WO2008147807A2 - Phyllosilicates en couches interagissant avec le cholestérol et procédés visant à réduire l'hypercholestérolémie chez un mammifère - Google Patents

Phyllosilicates en couches interagissant avec le cholestérol et procédés visant à réduire l'hypercholestérolémie chez un mammifère Download PDF

Info

Publication number
WO2008147807A2
WO2008147807A2 PCT/US2008/064351 US2008064351W WO2008147807A2 WO 2008147807 A2 WO2008147807 A2 WO 2008147807A2 US 2008064351 W US2008064351 W US 2008064351W WO 2008147807 A2 WO2008147807 A2 WO 2008147807A2
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol
layered phyllosilicate
phyllosilicate material
group
layered
Prior art date
Application number
PCT/US2008/064351
Other languages
English (en)
Other versions
WO2008147807A3 (fr
Inventor
Jerald W. Darlington, Jr.
Panayiotis P. Constantinides
Original Assignee
Amcol International Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amcol International Corporation filed Critical Amcol International Corporation
Priority to DK08780675.8T priority Critical patent/DK2167069T3/da
Priority to EP08780675A priority patent/EP2167069B1/fr
Priority to PL08780675T priority patent/PL2167069T3/pl
Priority to CA002688111A priority patent/CA2688111A1/fr
Priority to AT08780675T priority patent/ATE530178T1/de
Publication of WO2008147807A2 publication Critical patent/WO2008147807A2/fr
Publication of WO2008147807A3 publication Critical patent/WO2008147807A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Definitions

  • This invention relates generally to methods and compositions for reducing hypercholesteremia in a mammalian subject.
  • Atherosclerosis is the most common cause of death and serious morbidity in the Western world. Atherosclerosis is one of three morphologically distinct forms of arteriosclerosis. Arteriosclerosis is the hardening of the arteries due to their thickening and loss of elasticity. Atherosclerosis occurs when irregularly distributed lipid deposits form in the inner coating of the vessels of the elastic arteries, such as the aorta, carotid and iliac, or the large and medium-sized muscular arteries, such as the coronary and popliteal. These lipid deposits, called atheromatous plaques, cause fibrosis and calcification which leads to coronary heart disease and myocardial infarction.
  • the plaques are comprised of cells, macrophages and other leukocytes, a connective tissue extra-cellular matrix and intracellular and extracellular lipid deposits.
  • the progression of atherosclerosis can be slowed by reducing the plasma cholesterol and cholesterol LDL levels.
  • Hypercholesterolemia or elevated blood cholesterol levels due to concentration of cholesterol in the cells and plasma, is also prevalent in the American population. Elevated total and LDL cholesterol levels are considered cardiovascular risk factors for coronary heart disease and myocardial infarction.
  • Cholesterol is the most abundant steroid in cell membranes and is essential to the growth and viability of cells. Cholesterol, free and in esterified form, is classified as a lipid andit is a component of lipoproteins, which are complexes of lipids (phospholipids and triglycerides) with proteins. There are four major categories of lipoproteins: chylomicrons, very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL). Chylomicrons transport some dietary cholesterol and mostly triglycerides from the intestines to the adipose tissue (also known as fat) and the liver.
  • VLDL very low density lipoproteins
  • LDL low density lipoproteins
  • HDL high density lipoproteins
  • VLDLs transport cholesterol and triglycerides made by the liver to adipose and other tissues.
  • LDL is a byproduct consisting of apolipoprotein and cholesterol that remains after the fat cells have removed the triglycerides from the VLDL.
  • LDLs transport cholesterol to the peripheral tissues (cells outside the liver and intestine) and regulate the endogenous cholesterol levels therein. LDL is often referred to as the "bad cholesterol” because high levels increase the risk of developing arteriosclerosis and hypercholesterolemia.
  • HDL known as the "good cholesterol," transports cholesterol from the peripheral tissues (and arterial walls) to the liver. HDLs operate as good cholesterol because they have an opposite function to than of LDLs.
  • LDL is the primary source of cholesterol in peripheral tissues, which do not synthesize cholesterol de novo. LDL is taken into these cells via endocytosis at LDL receptor cites.
  • the molecular genetics and cellular biology of the LDL receptor has been characterized by Goldstein and Brown (Atheroscler Suppl. 2004 Oct;5(3):57-9).
  • the LDL receptor is essential to cholesterol metabolism. When cholesterol is abundant inside the cell, there is no synthesis of LDL receptors, and thus cholesterol uptake from plasma cholesterol is blocked. The absence of the LDL receptor leads to hypercholesterolemia and atherosclerosis.
  • the average person consumes between 350-400 mg of cholesterol daily, while the recommended intake is around 300 milligrams.
  • Increased dietary cholesterol consumption especially in conjunction with a diet high in saturated fat intake, can result in elevated serum cholesterol.
  • Having an elevated serum cholesterol level is a well-established risk factor for heart disease and therefore there is a need to mitigate the undesired effects of cholesterol accumulation.
  • High cholesterol levels are generally considered to be those total cholesterol levels at 200 milligrams and above or LDL cholesterol levels at 130 milligrams and above. By lowering the total system LDL cholesterol level, it is believed that certain health risks, such as coronary disease and possibly some cancers, that are typically associated with high cholesterol levels, can be reduced by not an insignificant amount.
  • lipid-lowering therapeutic agents (1) bile acid-binding resins, (2) niacin; or (3) 3-hydroxy-3-methylglutaryl-coenzyme A (HMG- CoA) reductase inhibitors.
  • HMG- CoA 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
  • These drugs cause respectively: (1) constipation, gastric discomfort, nausea, hemorrhoidal bleeding; (2) arrhythmias, peptic ulcer disease, glucose intolerance, hepatic dysfunction; and (3) abnormal liver function and myositis. If these agents, normally prescribed as the first line of therapy are not successful, fibric acid derivatives like gemfibrozil are often administered.
  • side-effects with this class of drugs such as lithogenicity of bile, nausea, abnormal liver functions and myositis.
  • the present invention relates generally to methods and compositions for reducing hypercholesteremia in a mammalian subject.
  • methods of reducing hypercholesteremia in a mammal comprise administering a layered phyllosilicate material to a mammal, wherein the layered phyllosilicate material comprises a layered phyllosilicate material (including, but not limited to, a hydrogen protonated layered phyllosilicate material), in an amount effective to reduce hypercholesteremia.
  • the method further comprises the step of administering a therapeutic agent (in addition to the layered phyllosilicate material) to the mammal in need of treatment.
  • the therapeutic agent is a cholesterol-reducing agent.
  • the therapeutic agent is a triglyceride-reducing agent.
  • the layered phyllosilicate material is administered concurrently with the therapeutic agent.
  • the layered phyllosilicate material is administered at different times than the therapeutic agent.
  • the mammal is a human. In other aspects, the mammal is animal selected from the group consisting of a horse, a cow, sheep, a pig, a llama, an alpaca, a goat, a dog, a cat, a mouse, a rat, a rabbit, a guinea pig and a hamster.
  • Also provided are methods of delivering a therapeutic agent to a mammal comprising administering a composition comprising a layered phyllosilicate material, wherein the layered phyllosilicate material comprises a layered phyllosilicate material (including, but not limited to, a hydrogen protonated layered phyllosilicate material), and a therapeutic agent to the mammal, wherein the therapeutic agent is a lipid-lowering therapeutic agent or a cholesterol-reducing therapeutic agent.
  • Contemplated therapeutic agents are described herein and include, but are not limited to, a nucleic acid, a protein, a polysaccharide, a drug and a small molecule drug.
  • the therapeutic agent is intercalated within the layered phyllosilicate material.
  • the therapeutic agent is selected from the group consisting of bile acid resins, statins, statin-related agent, niacin, fibrates, cholesterol absorption inhibitors, lecithin, phytosterols and epigallocatechin gallate.
  • the therapeutic agent is a polysaccharide selected from the group consisting of alginate, pectin and modifications thereof, gellan gum, xanthan gum and zooglan.
  • the layered phyllosilicate material useful for cholesterol reduction includes the following clay minerals: montmorillonite, particularly sodium montmorillonite, protonated hydrogen montmorillonite, magnesium montmorillonite and/or calcium montmorillonite; nontronite; beidellite; laponite; yakhontovite; zincsilite; volkonskoite; hectorite; saponite; ferrosaponite; sauconite; swinefordite; pimelite; sobockite; stevensite; svinfordite; vermiculite; synthetic clays; mixed layered illite/smectite minerals, such as rectorite, tarosovite, and ledikite; admixtures of illites with the clay minerals named above, and the magnesium aluminum silicates.
  • montmorillonite particularly sodium montmorillonite, protonated hydrogen montmorillonite, magnesium montmorillonite and/or calcium montmorillonite
  • nontronite beide
  • the layered phyllosilicate material is a smectite clay selected from the group consisting of bentonite, montmorillonite, nontronite, beidellite, laponite, hectorite and saponite.
  • One preferred layered phyllosilicate material comprises a smectite clay having at least 80%, preferably at least 95% interlayer, exchangeable homoionic cations, preferably hydrogen ions, based on the total of number of interlayer, exchangeable cations.
  • layered phyllosilicate materials include protonated hydrogen ion-exchanged layered phyllosilicate materials; protonated onium ion-exchanged layered phyllosilicate materials (protonated organoclays); smectite clays having a particle size less than 74 ⁇ m, preferably less than 50 ⁇ m, more preferably less than 20 ⁇ m; and exfoliated smectite clays, including individual clay platelets and tactoids of 5 or less platelet layers.
  • the layered phyllosilicate material can be ingested in the form of a powder or an aqueous and/or organic liquid solution or suspension which can further be filled into a capsule or compressed into a tablet for internal interaction with dietary cholesterol within the gastrointestinal tract that has been or is about to be ingested.
  • the cholesterol remains sorbed on the clay and is prevented from being absorbed into the bloodstream.
  • compositions comprising the layered phyllosilicate material and a pharmaceutically acceptable carrier, diluent or adjuvant are also provided.
  • methods of reducing hypercholesteremia in a mammal comprise administering to said mammal a therapeutically-effective amount of a combination therapy comprising (a) a layered phyllosilicate material and (b) a therapeutic agent in addition to the layered phyllosilicate material.
  • the therapeutic agent comprises a cholesterol-reducing agent selected from the group consisting of a statin-related agent (including, but not limited to, lovastatin, atorvastatin, pravastatin, simvastatin and fluvastatin), nicotinic acid, a fibrate (including, but not limited to, bezafibrate, ciprofibrate, clofibrate, gemfibrozil and fenofibrate), bile acid resin(s) (including, but not limited to, cholestyramine, colestipol and cholsevelam), a cholesterol absorption inhibitor (including, but not limited to, ezetimibe), salicylic acid, a phytosterol (including, but not limited to, stigmastanol, sitosterol, sitostanol and policosanol), an alginate or a pectin, lecithin and a nutraceutical associated with cholesterol reduction (including, but not limited to
  • the therapeutic agent is a triglyceride reducing agent.
  • the layered phyllosilicate material is administered concurrently with the therapeutic agent. In other variations, the layered phyllosilicate material is administered at different times than the therapeutic agent.
  • Figure 1 shows the level of total plasma cholesterol of the subjects fed the high fat/cholesterol for four weeks prior to drug treatment.
  • Figure 2 shows the level of ApoB cholesterol of the subjects fed the high fat/cholesterol for four weeks prior to drug treatment.
  • Figure 3 shows the level of HDL cholesterol of the subjects fed the high fat/cholesterol for four weeks prior to drug treatment.
  • Figure 4 shows the level of total plasma triglycerides of the subjects fed the high fat/cholesterol for four weeks prior to drug treatment.
  • Figure 5 shows the effects of Compounds A, B and C and Simvastatin on total plasma cholesterol levels compared to a control.
  • Figure 6 shows the effects of Compounds A, B and C and Simvastatin on total plasma triglyceride levels compared to a control.
  • Figure 7 shows the effects of Compounds A, B and C and Simvastatin on HDL cholesterol levels compared to a control.
  • Figure 8 shows the effects of Compounds A, B and C and Simvastatin on total ApoB levels compared to a control.
  • Figure 9 shows the effects of various layered phyllosilicate materials compared to controls in a severe dyslipidemic model.
  • Figure 10 shows the effects of various hydrogen protonated layered phyllosilicate materials compared to controls in a severe dyslipidemic model.
  • Figure 11 shows the effects of various layered phyllosilicate materials (in area under curve values) compared to controls in a severe dyslipidemic model.
  • Figure 12 shows the effects of various hydrogen protonated layered phyllosilicate materials (in area under curve values) compared to controls in a severe dyslipidemic model.
  • Figure 13 shows the effects of a hydrogen protonated layered phyllosilicate material (in area under curve values) compared to stigmastanol and ezetimibe in a severe dyslipidemic model.
  • the present invention is directed to the discovery that administration of a layered phyllosilicate material reduced total plasma cholesterol in a mammalian subject with severe dyslipidemia and therefore can be used as a therapeutic aid for reducing and/or altering cholesterol levels in mammals.
  • the layered phyllosilicate material may optionally be formulated in a composition comprising an agent that reduces cholesterol in mammals by the same or different mechanism.
  • the invention therefore describes various therapeutic compositions and methods for using the layered phyllosilicate material.
  • One particular advantage of the layered phyllosilicate material of the present invention is the fact that due to their surface charge and molecular size, the phyllosilicate material cannot be taken up by cells or cross mucosal membranes and thus toxicity reactions seen with small molecule drugs can be avoided.
  • Ranges may be expressed herein as from “about” or “approximately” one particular value and/or to “about” or “approximately” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,” it will be understood that the particular value forms another embodiment.
  • sorption or "sorb” refers to the action of either absorption or adsorption.
  • the terms "therapeutically effective” or “amount sufficient” refers to when a composition or method of the invention is properly administered in vivo to a mammal, including humans, a measurable beneficial effect occurs.
  • exemplary beneficial effects include measurable reduction in the level of cholesterol and/or LDL and/or triglycerides in the blood of the mammal; reduction of clinically verifiable and/or patient-reported level of high cholesterol and/or LDL and/or triglycerides or complete resolution or curing of the elevated LDL and/or cholesterol and/or triglyceride condition or other diseases.
  • Normal and elevated levels of total cholesterol, LDL and triglycerides in blood are set forth in Table 1. Cholesterol levels can be measured by withdrawing blood from a patient and performing standard blood chemistry tests thereon.
  • hypocholesteremia or “hypercholesterolemia” as used herein mean the presence of elevated levels of cholesterol in the blood of a mammal.
  • the terms “concurrently” and “concurrent administration” mean that the layered phyllosilicate material and a therapeutic agent are administered to the subject either (a) simultaneously in time (optionally by formulating the two together in a common carrier), or (b) at different times during the course of a common treatment schedule. In the latter case, the two compounds are administered sufficiently close in time to achieve the intended effect.
  • the term "Phyllosilicate” or "layered phyllosilicate material” shall mean clay minerals, e.g., montmorillonite, particularly sodium montmorillonite, magnesium montmorillonite and/or calcium montmorillonite; protonated montmorillonite; nontronite; beidellite; laponite; yakhontovite; zincsilite; volkonskoite; hectorite; saponite; ferrosaponite; sauconite; swinefordite; pimelite; sobockite; stevensite; svinfordite; vermiculite; synthetic clays; mixed layered illite/smectite minerals, such as rectorite, tarosovite, and ledikite; admixtures of illites with the clay minerals named above, and the magnesium aluminum silicates.
  • montmorillonite particularly sodium montmorillonite, magnesium montmorillonite and/or calcium montmorillonite
  • Homoionic Phyllosilicate shall mean a layered Phyllosilicate material that has been purified by ion-exchange, for example, as described in this assignee's U.S. Patent No. 6,050,509, to contain at least 90% of a single interlayer exchangeable cation, in relation to all interlayer exchangeable cations, from periodic table groups Ia, 2a, 3b, 4b, 5b, 6b, 7b, 8, Ib, 2b, 3a, tin and lead; or a protonated onium ion compound, as the interlayer exchangeable cations.
  • Platinum shall mean individual layers of a Phyllosilicate.
  • Intercalate or “Intercalated” shall mean a phyllosilicate material that includes an onium ion spacing agent, preferably a protonated onium ion spacing agent, disposed between adjacent platelets of the layered Phyllosilicate material to increase the interlayer spacing between the adjacent platelets by at least 3 A, preferably at least 5 A, to an interlayer spacing, for example, of at least about 8A, preferably at least about 1OA.
  • an onium ion spacing agent preferably a protonated onium ion spacing agent
  • Intercalation shall mean a process for forming an Intercalate.
  • Onium Ion Intercalant or "Onium Ion Spacing Agent” or “Onium Ion Compound” shall mean an organic compound, preferably a protonated organic compound, that includes at least one positively charged atom selected from the group consisting of a nitrogen atom, a phosphorous atom, a sulfur atom or an oxygen atom, preferably a quaternary ammonium compound, and when dissolved in water and/or an organic solvent, an anion dissociates from the onium ion spacing agent leaving an onium cation that can ion-exchange with a silicate platelet exchangeable cation of the Phyllosilicate, e.g., Na + , Ca +2 , Li + , Mg +2 , Al +3 , or K + .
  • a silicate platelet exchangeable cation of the Phyllosilicate e.g., Na + , Ca +2 , Li + , Mg +2 , Al +3 , or K + .
  • Intercalating Carrier shall mean a carrier comprising water and/or an organic liquid to form an Intercalating Composition capable of achieving Intercalation of an onium ion spacing agent which ion-exchanges with exchangeable interlayer cations of the layered Phyllosilicate.
  • Tactoid shall mean a stack of individual clay platelet layers having ten or fewer platelets, preferably five or fewer platelets that result from partial exfoliation of a layered phyllosilicate material.
  • Intercalating Composition shall mean a composition comprising one or more onium ion spacing agents, an Intercalating Carrier for the onium ion spacing agent, and a layered Phyllosilicate.
  • Exfoliate or “Exfoliated” shall mean individual platelets of an Intercalated layered Phyllosilicate so that adjacent platelets of the Intercalated layered Phyllosilicate can be dispersed individually throughout a carrier material, such as water, a polymer, an alcohol or glycol, or any other organic liquid, together with or without tactoids of 2-20 layers of non- exfoliated or partially exfoliated platelets.
  • a carrier material such as water, a polymer, an alcohol or glycol, or any other organic liquid
  • Exfoliation shall mean a process for forming an Exfoliate from an Intercalate.
  • a preferred layered phyllosilicate material useful for interaction with cholesterol comprises a smectite clay having, as a starting material, sodium or calcium ions as its predominant interlayer exchangeable cation, and that has been purified and ion-exchanged in accordance with this assignee's U.S. Patent No. 6,050,509, hereby incorporated by reference.
  • the ion-exchange process can be used to provide a homoionic layered phyllosilicate material or can be used to provide the phyllosilicate with mixed cations from the periodic table groups Ia, Ib, 2a, 2b, 3a, 3b, 4b, 5b, 6b, 7b, 8, tin, hydrogen, lead, and/or protonated onium ions, within any percentage of the phyllosilicate exchangeable cations (1-99% of the exchangeable cations).
  • the smectite clay slurry is pumped to a series of ion exchange columns where any undesirable cation is exchanged with a desirable cation.
  • any element can be exchanged for the interlayer cations of a phyllosilicate for cholesterol interaction, including hydrogen and/or one or more elements from the following groups of the periodic table: group Ia (e.g., lithium, sodium, potassium) group 2a (e.g., magnesium, calcium, barium) group 3b (e.g., lanthanium), group 4b (e.g., titanium) group 5b (e.g., vanadium), group 6b (e.g., chromium), group 7b (e.g., manganese) group 8 (e.g., iron, cobalt, nickel, platinum), group Ib (e.g., copper, gold, silver), group 2b (e.g., zinc, cadmium) group
  • group Ia e.g., lithium, sodium, potassium
  • group 2a e.g., magnesium, calcium, barium
  • group 3b e.g., lanthanium
  • group 4b e.g., titanium
  • 5b
  • Homoionic hydrogen ion-exchanged layered phyllosilicates are formed as follows: A purified sodium exchanged clay was dispersed into filtered DI water to make a 3 wt% clay slurry. The mixture was mixed thoroughly with a Silverson homogenizer. The pH value of the starting clay slurry was about 10.
  • the crude layered phyllosilicate deposits initially include one or more of the following non-smectite impurities: (SiO 2 ), feldspar (KAlSi 3 O 8 ), opal-CT (SiO 2 ); gypsum (CaSO 4 '2H 2 O); albite (NaAlSi 3 O 8 ); anorthite (CaAl 12 Si 2 O 8 ); orthoclase (KAlSi 3 O 8 ); apatite (Ca 5 (PO 4 ) 3 (F,C1,OH)); halite (NaCl); calcite (CaCO 3 ); dolomite (CaMg(COs) 2 ; sodium carbonate (Na 2 CO 3 ); siderite (FeCO 3 ) biotite (K(Mg 5 Fe) 3 (AlSi 3 Oi 0 ) (OH) 2 ;
  • the layered phyllosilicate is dispersed (slurried) in water, preferably at a concentration of about 10% to about 15% by weight, based on the total weight of phyllosilicate and water.
  • the preferred layered phyllosilieate is a smectite clay, including but not limited to a montmorillonite clay, that is predominantly (greater than about 50% by weight) sodium or calcium (sodium or calcium ions outnumber any other cation in the interlayer spaces between adjacent clay platelets) montmorillonite clay so that the concentration of clay dispersed in water can be as high as about 15% by weight. If, for example, a sodium montmorillonite clay is dispersed in water, the higher swelling capacity of sodium montmorillonite in water will result in a viscosity that is too high for handling at a concentration of about 6-10% by weight.
  • the clay dispersed in water is a montmorillonite clay having predominantly (at least 50% by number) multivalent cations, i.e., Ca + " in the interlayer space, such as calcium montmorillonite clay. If the clay is not predominantly a multivalent clay, such as calcium montmorillonite, it can be ion-exchanged sufficiently to provide predominantly multivalent ions in the interlayer spaces between montmorillonite clay platelets.
  • the clay slurry is then directed into a series of cascaded hydrocyclones of decreasing size, each hydrocyclone capable of removing impurities of at least a particular size, particularly the impurities having a size greater than about 74 microns.
  • the resulting clay, separated from the impurities has a particle size such that at least about 90% by volume of the clay particles have a size below about 74 microns, preferably below about 50 microns, more preferably below about 20 microns.
  • the clay slurry is then directed upwardly through a cation exchange column that removes multivalent interlayer cations from the montmorillonite clay (e.g., divalent and/or trivalent cations) and substitutes monovalent cations such as sodium, lithium and/or hydrogen for the multivalent cations within the interlayer spaces between platelets of the montmorillonite clay.
  • a cation exchange column that removes multivalent interlayer cations from the montmorillonite clay (e.g., divalent and/or trivalent cations) and substitutes monovalent cations such as sodium, lithium and/or hydrogen for the multivalent cations within the interlayer spaces between platelets of the montmorillonite clay.
  • the clay After essentially complete ion exchange, such that the clay has at least 90%, preferably at least 95%, more preferably at least 99%, by number, monovalent cations in the interlayer spaces, the clay preferably is then directed into a high speed centrifuge where the clay is subjected to centrifugal force equal to, for example, at least about 2,000 G (forces of gravity) up to about 4,000 G, preferably about 2,500 G to about 3,500 G, capable of removing clay particle sizes between about 5 microns and about 74 microns, such that the remaining montmorillonite clay particles, having less than about 50 by weight crystalline and amorphous non-smectite clay impurities, preferably less than about 5% by weight impurities therein, have a particle size of about 10 microns or less, preferably about 8 microns or less, and have an average particle size less than about 3 microns, preferably less than about 2 microns.
  • the clay should first be conditioned or treated for removal of all multivalent, e.g., divalent and trivalent, interlayer cations by substitution of the multivalent cations with one or more monovalent cations, such as sodium ions, or protonated onium ions, in order to provide effective removal of the smallest impurities, for example, in a high speed (2,000-4,000 G) centrifuge.
  • multivalent e.g., divalent and trivalent, interlayer cations
  • monovalent cations such as sodium ions, or protonated onium ions
  • the product from primary and secondary one inch hydrocyclones are fed by gravity to an ion-exchange feed tank where the clay/water slurry, including impurities, are maintained at a clay concentration of about 1-7% by weight, preferably about 3-7% by weight, based on the total weight of material in the ion-exchange feed tank.
  • the clay slurry from the ion-exchange feed tank is pumped to a series of ion-exchange columns where the interlayer clay cations are exchanged with cations from periodic table groups Ia, Ib, 2a, 2b, 3a, 3b, 4b, 5b, 6b, 7b, 8, tin or lead, preferably sodium.
  • Ion-exchange is achieved, for example, by contact with an ion-exchange resin, preferably PUROLITE C-100, obtained from The PUROLITE Company, a polystyrene cross linked with divinyl benzene, in spherical bead form, in the sodium ionic form, having an 8% by weight divinyl benzene content to produce a sodium exchanged clay.
  • an ion-exchange resin preferably PUROLITE C-100, obtained from The PUROLITE Company, a polystyrene cross linked with divinyl benzene, in spherical bead form, in the sodium ionic form, having an 8% by weight divinyl benzene content to produce a sodium exchanged clay.
  • PUROLITE C-100 obtained from The PUROLITE Company
  • Amberlite FPC23 H available from Rohm & Hass to produce a protonated form.
  • the product from a secondary one inch hydrocyclone includes at least about 90% by number particles having a size less than about 50 microns, preferably less than about 20 microns, more preferably less than about 10 microns, a mean particle size less than about 10 microns, and a median particle size less than about 5 microns.
  • the phyllosilicate material e.g., sodium and/or calcium bentonite, or any sodium and/or calcium smectite clay, should be swelled or intercalated, in the preferred embodiment, by sorption of an onium ion spacing agent.
  • compositions and methods described herein are described by way of the preferred embodiment via expanding the interlaminar spacing between adjacent platelets of a layered phyllosilicate material by intercalating onium ions between the silicate platelets, the increased interlaminar spacing also can be achieved by intercalating one or more polymers, a silane coupling agent, or by an acidification technique, by substitution with hydrogen (ion- exchanging the interlayer cations with hydrogen by use of an acid or ion-exchange resin) as disclosed in the Deguchi U.S. Patent No. 5,102,948, and in the Lan, et al. U.S. Patent No. 5,853,886, both patents hereby incorporated by reference.
  • the extremely small size of the individual platelets and clay tactoids should permit interaction of cholesterol.
  • Sorption of the onium ion spacing agent should be sufficient to achieve expansion of the interlayer spacing of adjacent platelets of the layered phyllosilicate material (when measured dry) by at least about 3 A, preferably at least about 5 A.
  • the onium ion spacing agent is introduced into the layered phyllosilicate galleries in the form of a solid or liquid composition (neat or aqueous, with or without an organic solvent, e.g., an aliphatic hydrocarbon, such as heptane to, if necessary, aid to dissolve the onium ion compound) having an onium ion spacing agent concentration sufficient to provide a concentration of about 5% to about 10% by weight phyllosilicate (90-95% water) and the onium ion compound is dissolved in the phyllosilicate slurry water, preferably at a molar ratio of onium ions to exchangeable interlayer cations of at least about 0.25: 1, more preferably at least about 0.5:1, most preferably at least about 1:1.
  • the onium ion-intercalated layered phyllosilicate then is separated from the water easily, since the phyllosilicate is now hydrophobic, and dried in an oven to less than about 15% water, preferably bone dry, before interaction with the cholesterol.
  • the onium ion spacing agent compound can be added as a solid with the addition to the layered phyllosilicate material/onium ion compound blend of preferably at least about 20% water, more preferably at least about 30% water or more, based on the dry weight of layered material.
  • the onium ion spacing agent cations intercalated via ion-exchange into the interlayer spaces between adjacent layered material platelets are primary, secondary, tertiary or quaternary onium ions having the following preferred structure:
  • R 1 , R 2 , R 3 and R 4 are H or organic moieties, such as linear or branched alkyl, aryl or aralkyl moieties having 1 to about 24 carbon atoms.
  • the more preferred protonated C 6 + onium ions are preferably quaternary ammonium ions having Formula 1, as follows:
  • Rj is a long chain alkyl moiety ranging from C 6 to C 24 , straight or branched chain, including mixtures of long chain moieties, i.e., C 6 , Cg, Qo, Ci 2 , Ci 4 , Ci 6 , Ci 8 , C 20 , C 22 and C 24 , alone or in any combination; and R 2 , R 3 and R 4 are moieties, same or different, selected from the group consisting of H, alkyl, benzyl, substituted benzyl, e.g., straight or branched chain alkyl-substituted and halogen-substituted; ethoxylated or propoxylated alkyl; ethoxylated or propoxylated benzyl, e.g., 1-10 moles of ethoxylation or 1-10 moles of propoxylation.
  • Preferred protonated onium ions include protonated octadecylamine, protonated hexyl amine; protonated octyl amine; protonated tallow amine; protonated tallow diamine; protonated tallow triamine; protonated tallow tetraamine; protonated hydrogenated tallow amine; protonated hydrogenated tallow diamine; protonated hydrogenated tallow triamine; protonated hydrogenated tallow tetraamine; protonated octadecyl amine; and mixtures thereof.
  • R is an organic spacing, backbone radical, straight or branched, preferably having from 2 to 24, more preferably 3 to 10 carbon atoms, in a backbone organic spacing molecule covalently bonded at its ends to charged N + , P + , S + and/or O + cations
  • R examples include substituted or unsubstituted alkylene, cycloalkenylene, cycloalkylene, arylene, alkylarylene, either unsubstituted or substituted with amino, alkylamino, dialkylamino, nitro, azido, alkenyl, alkoxy, cycloalkyl, cycloalkenyl, alkanoyl, alkylthio, alkyl, aryloxy, arylalkylamino, alkylamino, arylamino, dialkylamino, diarylamino, aryl, alkylsufinyl, aryloxy, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfinyl, alkoxycarbonyl, arylsulfonyl, or alkylsilane.
  • Rl examples include non-existent; H; alkyl having 1 to 22 carbon atoms, straight chain or branched; cycloalkenyl; cycloalkyl; aryl; alkylaryl, either unsubstituted or substituted or substituted with amino, alkylamino, dialkylamino, nitro, azido, alkenyl, alkoxy, cycloalkyl, cycloalkenyl, alkanoyl, alkylthio, alkyl, aryloxy, arylalkylamino, alkylamino, arylamino, dialkylamino, diarylamino, aryl, alkylsufinyl, aryloxy, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfinyl, alkoxycarbonyl, arylsulfonyl, or alkylsilane.
  • alkylenes such as methylene, ethylene, octylene, nonylene, tert- butylene, neopentylene, isopropylene, sec-butylene, dodecylene and the like; alkenylenes such as 1-propenylene, 1-butenylene, 1-pentenylene, i-hexenylene, 1-heptenylene, 1-octenylene and the like; cycloalkenylenes such as cyclohexenylene, cyclopentenylene and the like; alkanoylalkylenes such as butanoyl octadecylene, pentanoyl nonadecylene, octanoyl pentadecylene, ethanoyl undecylene, propanoyl hexadecylene and the like; alkylaminoalkylenes, such as methylamino oct
  • Such tetra-, tri-, and di-ammonium, -sulfonium, -phosphonium, -oxonium; ammonium/sulfonium; ammonium/phosphonium; ammonium/oxonium; phosphomum/oxonium; sulfonium/oxonium; and sulfonium/phosphonium radicals are well known in the art and can be derived from the corresponding amines, phosphines, alcohols or ethers, and sulfides.
  • Other useful spacing agent compounds are multi-onium ion compounds that include at least two primary, secondary, tertiary or quaternary ammonium, phosphonium, sulfonium, and/or oxonium ions having Formula 2, as follows:
  • R is an alkylene, aralkylene or substituted alkylene charged atom spacing moiety, preferably ranging from C 3 to C 24 , more preferably about C 3 to C 6 for relatively high charge density (150 milliequivalents/100 grams C.E.C. to 70 milliequivalents/100 grams C.E.C.) layered materials; and preferably from C 6 to C 12 for medium to low charge density (70 milliequivalents/100 grams C.E.C. to 30 milliequivalents/100 grams C.E.C.) layered materials.
  • R can be straight or branched chain, including mixtures of such moieties, i.e., C 4 , C5, C 6 , C 7 , Cg, C9, Cio, Cn, Ci 2 , C13, Cj 4 , C15, Ci 6 , Cj 7 , Cjg, C19, C 2 o, C 21 , C 22 , C 23 and C 24 , alone or in any combination; and Ri, R 2 , R 3 and R 4 are moieties, same or different, selected from the group consisting of hydrogen, alkyl, aralkyl, benzyl, substituted benzyl, e.g., straight or branched chain alkyl-substituted and halogen-substituted; ethoxylated or propoxylated alkyl; ethoxylated or propoxylated benzyl, e.g., 1-10 moles of ethoxylation or 1-10 moles of propoxylation.
  • moieties
  • Z 1 and Z 2 same or different, may be non-existent, or may be any of the moieties described for Rj , R 2 , R 3 or R 4 . Also, one or both of Z and Z" may include one or more positively charged atoms or onium ion molecules.
  • Any swellable layered phyllosilicate material that sufficiently sorbs the onium ion spacing agent to increase the interlayer spacing between adjacent phyllosilicate platelets by at least about 3 A, preferably at least about 5 A, can be used in the practice of this invention.
  • Useful swellable layered materials include phyllosilicates, such as smectite clay minerals, e.g., montmorillonite, particularly sodium montmorillonite, magnesium montmorillonite and/or calcium montmorillonite; nontronite; beidellite; laponite; yakhontovite; zincsilite; volkonskoite; hectorite; saponite; ferrosaponite; sauconite; swinefordite; pimelite; sobockite; stevensite; svinfordite; vermiculite; synthetic clays; mixed layered illite/smectite minerals, such as rectorite, tarosovite, and ledikite; admixtures of illites with the clay minerals named above, magnesium aluminum silicates; ion-exchanged phyllosilicates, including homoionic and/or protonated phyllosilicates; and mixtures of any two or more of the
  • Exemplary mixtures include any of the above-listed phyllosilicates, wherein one of the above-listed phyllosilicates is present in amount ranging from about l%-99% wt. and another phyllosilicate is present in an amount ranging from 99%- 1% wt.; or wherein one of the above-listed phyllosilicates is present in amount greater than 50% wt and another phyllosilicate is present in an amount less than 50% wt; or wherein one of the above-listed phyllosilicates is present in amount of 50% wt and a second phyllosilicate is present in an amount of 50%; or wherein one of the above-listed phyllosilicates is present in amount of about 10% wt and another phyllosilicate is present in an amount of about 90%; or wherein one of the above-listed phyllosilicates is present in amount of about 20% wt and another phyllosilicate is present in an amount of about 80%; or
  • Preferred swellable layered materials are pliyllosilicates of the 2:1 type having a negative charge on the layers ranging from about 0.15 to about 0.9 charges per formula unit and a commensurate number of exchangeable metal cations in the interlayer spaces.
  • Most preferred layered materials are smectite clay minerals such as montmorillonite, nontronite, beidellite, volkonskoite, hectorite, saponite, sauconite, sobockite, stevensite, and svinfordite.
  • interlayer spacing refers to the distance between the internal faces of the adjacent phyllosilicate layers as they are assembled in the layered material before any delamination (exfoliation) takes place.
  • the preferred clay materials generally include interlayer cations such as Na + , Ca +2 , K + , Mg +2 , Al +J+ , NH 4 and the like, including mixtures thereof, and can be ion-exchanged to include other cations such as the elements from period table group Ia, Ib, 2a, 2b, 3a, 3b, 4b, 5b, 6b, 7b, 8, tin and lead.
  • the onium ions may be introduced into (sorbed within) the interlayer spaces of the layered phyllosilicate in a number of ways.
  • the phyllosilicate material is slurried in water, e.g., at 5-20% by weight layered phyllosilicate material and 80-95% by weight water, and the onium ion compound is dissolved in the water in which the phyllosilicate material is slurried.
  • the onium ion compound can be dissolved first in an organic solvent, e.g., propanol.
  • the phyllosilicate material then is separated from the slurry water and dried suspending the individual silicate platelets and tactoids in a liquid carrier.
  • the phyllosilicate/onium ion intercalating composition preferably contains a molar ratio of onium ions to layered phyllosilicate of at least 0.25:1, more preferably at least 0.5:1 for the onium ions to exchange interlayer cations with the smectite clay, most preferably 1:1, based on the dry weight of the phyllosilicate, so that the resulting onium ion- intercalated phyllosilicate has interior platelet surfaces that are sufficiently hydrophobic and sufficiently spaced for exfoliation and suspension of the individual platelets and tactoids in a liquid carrier.
  • the onium ion carrier (preferably water, with or without an organic solvent) can be added by first solubilizing or dispersing the onium ion compound in the carrier; or a dry onium ion compound and relatively dry layered phyllosilicate (preferably containing at least about 4% by weight water) can be blended and the intercalating carrier added to the blend, or to the phyllosilicate prior to adding the dry onium ion.
  • a dry onium ion compound and relatively dry layered phyllosilicate preferably containing at least about 4% by weight water
  • the amount of water can vary substantially, e.g., from about 4% by weight, preferably from a minimum of at least about 30% by weight water, with no upper limit to the amount of water in the intercalating composition (the phyllosilicate intercalate is easily separated from the intercalating composition due to its hydrophobicity after onium ion treatment).
  • the onium ion intercalating carrier e.g., water, with or without an organic solvent
  • the onium ion compound molecules may be performed by exposing the phyllosilicate to a dry or liquid onium ion compound in the onium ion intercalating composition containing at least about 2% by weight, preferably at least about 5% by weight onium ion compound, more preferably at least about 10% onium ion compound, based on the dry weight of the layered phyllosilicate material.
  • the phyllosilicate preferably containing at least about 4% by weight water, more preferably about 10% to about 15% by weight water, is blended with water and/or organic solvent solution of an onium ion spacing agent compound in a ratio sufficient to provide at least about 5% by weight, preferably at least about 10% by weight onium ion compound, based on the dry weight of the layered phyllosilicate material.
  • the onium ion spacing agents have an affinity for the phyllosilicate so that they are sorbed between, and are ion-exchanged with the cations on the inner surfaces of the silicate platelets, in the interlayer spaces.
  • the invention provides various in vivo methods of using the layered phyllosilicate material of the invention.
  • the layered phyllosilicate material of the invention is useful to treat hypercholesteremia in a mammal as well as for providing a delivery vehicle for therapeutic agents (including, but not limited to, cholesterol-lowering agents, triglyceride-lowering agents and other lipid-lowering agents). .
  • the layered phyllosilicate material reduces dietary cholesterol by removing cholesterol from the gastrointestinal tract
  • removal of cholesterol from the gastrointestinal tract using the layered phyllosilicate material described herein is by one or more mechanisms selected from the group consisting of absorption, adsorption, ionic complexing, electrostatic complexing, chelation, hydrogen bonding, ion-dipole, dipole/dipole, Van Der Waals forces, and any combination thereof.
  • the layered phyllosilicate material interferes with the pancreatic lipase mechanism similar to that of the anti-obesity drug Orlistat (Xenical®).
  • Orlistat reduces intestinal fat absorption by inhibiting pancreatic lipase.
  • Another lipase inhibitor called GT 389-255, is being developed by Peptimmune.
  • GT-389-255 is a combination of an inhibitor and a polymer designed to bind the undigested triglycerides therefore allowing increased fat excretion without side effects such as oily stools that occur with Orlistat.
  • the layered phyllosilicate material suppresses cholesterol adsorption by blocking the degradative process of cholesterol within the gastrointestinal tract resulting in decreased solubility of cholesterol during intestinal diffusion (Wang et al, Annu. Rev. Physiol, 69:221-48, 2007)
  • the layered phyllosilicate material increases the thickness of the unstirred water layer covering the mucosa of the small intestine, thereby reducing cholesterol diffusion.
  • the layered phyllosilicate material interferes with micelle formation of bile acids around the cholesterol present in the gastrointestinal tract. As a result, the cholesterol remains insoluble and is not transported to and therefore not absorbed by the unstirred water layer of the microvilli.
  • the layered phyllosilicate increases the viscosity of the intestinal contents and reduces cholesterol absorption efficiency (Carr et al., J. Nutr. 126: 1463-1469, 1996).
  • the layered phyllosilicate material interacts with micelles containing cholesterol and reduces the rate of cholesterol diffusion from a micelle to the mucosa of the small intestine. As a result, the amount of cholesterol absorbed is reduced.
  • the invention includes a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a layered phyllosilicate material as described herein in an amount effective to reduce the level of total plasma cholesterol in said mammal.
  • the layered phyllosilicate material is formulated into a composition comprising a pharmaceutically acceptable carrier, diluent or excipient.
  • the mammal is human. In other embodiments, the mammal is an animal. Exemplary animals include, but are not limited to, farm animals such as horses, cows, sheep, pigs, alpacas, llamas and goats; companion animals such as dogs and cats; exotic and/or zoo animals; laboratory animals including mice, rats, rabbits, guinea pigs and hamsters.
  • farm animals such as horses, cows, sheep, pigs, alpacas, llamas and goats
  • companion animals such as dogs and cats
  • exotic and/or zoo animals laboratory animals including mice, rats, rabbits, guinea pigs and hamsters.
  • a composition comprising the layered phyllosilicate material will further comprise a therapeutic agent in addition to the layered phyllosilicate material.
  • the therapeutic agent can be a small molecule or macromolecule such as peptide, protein or nucleic acid.
  • the therapeutic agent is selected from the group consisting of cholesterol absorption inhibitors (including, but not limited to, ezetimibe (ZETIA, EZETROL, EZEMIBE, Merck, Schering-Plough); lipase inhibitors, see e.g., U.S. Patent No.
  • 6,432,200 including, but not limited to, Orlistat (Xenical®) and GT 389-255
  • bile-acid- binding resins which interrupt the recycling of bile acids from the intestine to the liver (including, but not limited to, cholestyramine (QUESTRAN LIGHT, Bristol-Myers Squibb), and colestipol hydrochloride (COLESTID, Pharmacia & Upjohn Company)
  • statins which inhibit cholesterol synthesis by blocking HMGCoA-- the key enzyme involved in cholesterol biosynthesis (including, but not limited to, lovastatin (MEVACOR, Merck & Co., Inc.), a natural product derived from a strain of Aspergillus, pravastatin (PRAVACHOL, Bristol- Myers Squibb Co.), and atorvastatin (LIPITOR, Warner Lambert) cerivastatin (BAYCOR (Bayer), fluvastatin (LESCOL (Sandoz)), and simvastatin (ZOCOR (
  • the layered phyllosilicate material is utilized as a delivery vehicle.
  • the layered phyllosilicate material is a delivery vehicle for nucleic acids and proteins.
  • the layered phyllosilicate material is a delivery vehicle for a therapeutic agent described herein. Binding of a therapeutic agent to a layered phyllosilicate material can improve its delivery and absorption through mucosal membranes, including the ocular, de ⁇ nal, nasal and intestinal membranes. Drug release from the layered phyllosilicates can be induced by pH, ionic strength changes, and/or in response to temperature, ionic current or ultrasound.
  • the layered phyllosilicate material is the delivery vehicle.
  • the layered phyllosilicate material is used in lieu of or in conjunction with other drug delivery vehicles known in the art in order to increase cell targeting membrane permeability and absorption.
  • drug delivery systems known in the art include, but are not limited to, those described in U.S. Patent Nos. 6,838,528; 6,797,704; 6,730,334; 6,706,289; 6,482,439; 6,443,989; 6,383,478; 6,165,440; 5,780,044; 5,759,563; 5,565,215; and U.S. Patent Application Publication Nos.
  • the layered phyllosilicate material alone, or in combination with one or more therapeutic agents as described herein, is administered by any route that delivers an effective dosage to the desired site of action, with acceptable (preferably minimal) side-effects.
  • routes of administration including for example, oral, rectal, vaginal, transmucosal, buccal or intestinal administration; parenteral delivery, including intraperitoneal intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, cutaneous or intradermal injections; respiratory or inhalation, nasal, pulmonary and topical application, including ocular and transdermal applications.
  • a "therapeutically effective amount” or an “effective amount” of a layered phyllosiiicate material or a composition comprising a layered phyllosiiicate material means a sufficient amount of the layered phyllosiiicate material is provided to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the layered phyllosiiicate material will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
  • the total daily dose of a layered phyllosiiicate material administered to a mammalian subject range from about 0.001 to about 200 mg/kg/day. If desired, the effective daily dose may be divided into multiple doses for purposes of administration; consequently, single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
  • the dosage regimen of a phyllosiiicate composition alone or in combination as described herein to be used in anti-cholesterol treatment will be determined by the attending physician considering various factors which modify the action of the phyllosiiicate, e.g., the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors.
  • Oral dosage forms include tablets, capsules, caplets, solutions, suspensions and/or syrups, and may also comprise a plurality of granules, beads, powders or pellets that may or may not be encapsulated.
  • Such dosage forms are prepared using conventional methods known to those in the field of pharmaceutical formulation and described in the pertinent texts, e.g., in Remington: The Science and Practice of Pharmacy, supra). Tablets and capsules represent the most convenient oral dosage forms, in which case solid pharmaceutical carriers are employed.
  • Tablets may be manufactured using standard tablet processing procedures and equipment.
  • One method for forming tablets is by direct compression of a powdered, crystalline or granular composition containing the active agent(s), alone or in combination with one or more carriers, additives, or the like.
  • tablets can be prepared using wet-granulation or dry-granulation processes. Tablets may also be molded rather than compressed, starting with a moist or otherwise tractable material.
  • tablets prepared for oral administration will generally contain other materials such as binders, diluents, lubricants, dis integrants, fillers, stabilizers, surfactants, preservatives, coloring agents, flavoring agents and the like. Binders are used to impart cohesive qualities to a tablet, and thus ensure that the tablet remains intact after compression.
  • Suitable binder materials include, but are not limited to, starch (including com starch and pregelatinized starch), gelatin, sugars (including sucrose, glucose, dextrose and lactose), polyethylene glycol, propylene glycol, waxes, and natural and synthetic gums, e.g., acacia sodium alginate, polyvinylpyrrolidone, cellulosic polymers (including hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, and the like), and Veegum. Diluents are typically necessary to increase bulk so that a practical size tablet is ultimately provided.
  • Suitable diluents include dicalcium phosphate, calcium sulfate, lactose, cellulose, kaolin, mannitol, sodium chloride, dry starch and powdered sugar.
  • Lubricants are used to facilitate tablet manufacture; examples of suitable lubricants include, for example, vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, com oil, and oil of theobroma, glycerin, magnesium stearate, calcium stearate, and stearic acid.
  • Disintegrants are used to facilitate disintegration of the tablet, and are generally starches, clays, celluloses, algins, gums or crosslinked polymers.
  • Fillers include, for example, materials such as silicon dioxide, titanium dioxide, alumina, talc, kaolin, powdered cellulose and microcrystalline cellulose, as well as soluble materials such as mannitol, urea, sucrose, lactose, dextrose, sodium chloride and sorbitol.
  • Stabilizers are used to inhibit or retard drug decomposition reactions that include, by way of example, oxidative reactions.
  • Surfactants may be anionic, cationic, amphoteric or nonionic surface active agents.
  • the dosage form may also be a capsule, in which case the layered phyllosilicate material-containing composition may be encapsulated in the form of a liquid or solid (including particulates such as granules, beads, powders or pellets).
  • Suitable capsules may be either hard or soft, and are generally made of gelatin, starch, or a cellulosic material, with gelatin capsules preferred.
  • Two-piece hard gelatin capsules are preferably sealed, such as with gelatin bands or the like. (See, for e.g., Remington: The Science and Practice of Pharmacy, supra), which describes materials and methods for preparing encapsulated pharmaceuticals .
  • Solid dosage forms may, if desired, be coated so as to provide for delayed release.
  • Dosage forms with delayed release coatings may be manufactured using standard coating procedures and equipment. Such procedures are known to those skilled in the art and described in the pertinent texts (See, for e.g., Remington: The Science and Practice of Pharmacy, supra).
  • a delayed release coating composition is applied using a coating pan, an airless spray technique, fluidized bed coating equipment, or the like.
  • Delayed release coating compositions comprise a polymeric material, e.g., cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose proprionate phthalate, polyvinyl acetate phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethylcellulose, hydroxypropyl methylcellulose acetate succinate, polymers and copolymers formed from acrylic acid, methacrylic acid, and/or esters thereof.
  • a polymeric material e.g., cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose proprionate phthalate, polyvinyl acetate phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl
  • sustained release dosage forms provide for drug release over an extended time period, and may or may not be delayed release.
  • sustained release dosage forms are formulated by dispersing a drug within a matrix of a gradually bioerodible (hydrolyzable) material such as an insoluble plastic, a hydrophilic polymer, or a fatty compound, or by coating a solid, drug-containing dosage form with such a material.
  • a gradually bioerodible (hydrolyzable) material such as an insoluble plastic, a hydrophilic polymer, or a fatty compound
  • Insoluble plastic matrices may be comprised of, for example, polyvinyl chloride or polyethylene.
  • Hydrophilic polymers useful for providing a sustained release coating or matrix cellulosic polymers include, without limitation: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, hydroxypropylcellulose phthalate, cellulose hexahydrophthalate, cellulose acetate hexahydrophthalate, and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, acrylic acid alkyl esters, methacrylic acid alkyl esters, and the like, e.g.
  • Fatty compounds for use as a sustained release matrix material include, but are not limited to, waxes generally (e.g., carnauba wax) and glyceryl tristearate
  • compositions may be administered orally, other modes of administration are contemplated as well.
  • modes of administration include transmucosal (e.g., U.S. Patent Nos. 5,288,498; 6,248,760; 6,355,248; 6,548,490, the disclosures of which are incorporated herein by reference in their entireties), transurethral (e.g., e.g., U.S. Patent Nos. 5,919,474 and 5,925,629, the disclosures of which are incorporated herein by reference in their entireties), vaginal or perivaginal (e.g., U.S. Patent Nos.
  • compositions of this invention can be employed in mixture with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for topical application which do not deleteriously react with the acid or the alcohol in the composition.
  • compositions of the invention can also include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
  • the layered phyllosilicate material of the invention is administered in a concentration (w/v) ranging from about 0.1% to about 20%, or from about 1% to about 10%, or in a concentration of about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19% or about 20%.
  • the invention further contemplates the administration of other therapeutic agents in addition to the layered phyllosilieate material which possess the capacity to reduce the level of cholesterol and/or LDL and/or triglycerides and/or other lipids in the blood of a mammal, and are considered useful in a composition in combination with the layered phyllosilieate material according to the present invention.
  • the layered phyllosilieate material and the therapeutic agent are administered simultaneously in a combined amount effective to produce the desired therapeutic outcome.
  • compositions or pharmacological formulations that includes all of the active agents, or by administering to the subject two distinct compositions or formulations, at the same time, wherein one composition includes the layered phyllosilieate material, and the second composition includes the therapeutic agent.
  • the layered phyllosilieate material and other therapeutic agent(s) may or may not exhibit the same mechanism by which they reduce the levels of total cholesterol (i.e., hypercholesteremia) and/or other lipids in a mammal.
  • the layered phyllosilieate material treatment may precede or follow therapy with another therapeutic agent by intervals ranging from minutes to weeks.
  • two or more therapeutic compositions are administered separately, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the second therapeutic agent and layered phyllosilieate material would still be able to exert an advantageously combined effect.
  • the therapeutic agent in the combination therapy is a statin- related agent.
  • statin-related refers to any statin drug that is presently on the market, or is modified from the presently marketed statin drugs, and has a therapeutic effect when combined with the layered phyllosilicate material described herein.
  • analogs and variants of preexisting statins are contemplated to be useful herein. Such analogs or variants may be produced through rational drug design techniques known to those of skill in the art.
  • statin drugs are known as HMGCoA reductase inhibitors. These drugs are presently in clinical use as drugs in the battle against high cholesterol and in the control of heart attacks, both recurrent and first heart attacks.
  • Statins are exemplified by lovastatin (CAS Registry No. 75330-75-5; also known as mevinolin or monacolin K), and analogs of this compound have been described in numerous publications and patents.
  • Exemplary statin compositions that are commercially available include LipitorTM (atorvastatin), PravacholTM (pravastatin), ZocorTM (simvastatin), MevacorTM (lovastatin), and Lescol TM (fluvastatin). Methods of preparing such compounds are well known to those of skill in the art (see e.g., U.S. Patent Nos.
  • statins are traditionally produced through fermentation using organisms from the Aspergillus genus, Monascus genus, Pleurotus genus, Coniothyrium genus and the like (see U.S. Patent No. 6,521,762 for review of such fermentation procedures).
  • statins as a pharmaceutical medicament have been described in e.g., the Physician's Desk Reference.
  • tablet formulations of LipitorTM atorvastatin calcium
  • atorvastatin calcium are described at pages 2547-2551 (Parke-Davis, NJ.) and 2610-2613 (Pfizer, NY) of the Physician's Desk Reference(57 th Edition, 2003).
  • These formulations are supplied as tablets of atorvastatin calcium containing 10 mg, 20 mg, 40 mg, 50 mg, and 80 mg atorvastatin.
  • the tablets are administered in doses ranging from 10 mg/day to 80 mg/day.
  • the compositions of LipitorTM presently being used to lower cholesterol in humans may be used in the combined treatments of the present invention to produce a therapeutic amelioration of HADDS and related lipodystrophy.
  • PravacholTM (pravastatin sodium; Bristol-Myers Squibb, NY), is another exemplary commercially available statin that may be used in the combined therapies of the present invention.
  • PravacholTM is supplied as a 10 mg, 20 mg, 40 mg, and 80 mg tablets. These tablets may be administered at a daily dose of ranging from 10 mg/day to 80 mg/day.
  • 40 mg/day are administered as a single daily dose, with or without food. However, it is generally appreciated that this dose may be increased or lowered depending on the level of renal and liver function of the patient being treated.
  • the administration doses and treatment guidelines for PravacholTM are discussed in further detail at pages 1101-1105 of the Physician's Desk Reference (57 th Edition, 2003) and may be used to provide guidance for the use of statins in the methods of the present invention.
  • ZocorTM (simvastatin; Merck & Co., Inc., NJ), is another exemplary statin composition that may be used in combination with the layered phyllosilicate material of the present invention.
  • Formulations of simvastatin are described at pages 2126-2131 of the Physician's Desk Reference (57 th Edition, 2003). The daily doses may range from 5 mg/day to 80 mg/day and those of skill in the art are referred to the Physician's Desk Reference for further guidance regarding treatment protocols that may be used and/or modified for the present invention.
  • MevacorTM lovastatin; Merck & Co., Inc. NY
  • Lescol TM fluvastatin
  • MevacorTM lovastatin; Merck & Co., Inc. NY
  • Lescol TM fluvastatin
  • Oral doses of the statins are particularly contemplated. Such oral doses may comprise the administration of between about 5 mg to about 80 mg statin drug on a daily basis. However, larger doses e.g., up to 200mg/day also may be used. Thus, the subject may receive 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 rag, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg or more statin drug orally. Of course it should be understood the subject may receive more or less of the statin. Also it should be understood that similar doses may be administered through other routine routes of administration. The statin may be delivered in a single dose or alternatively may be subdivided and administered in multiple doses over a given period of time.
  • the therapeutic agent in the combination therapy is nicotinic acid. Nicotinic acid (niacin) lowers total and LDL cholesterol and raises HDL cholesterol, and also lowers triglycerides. The dose of niacin required to lower cholesterol is about 100 times more than the Recommended Daily Allowance (RDA) for niacin and thus can potentially be toxic. Therefore, the drug must be taken under a doctor's care.
  • RDA Recommended Daily Allowance
  • the therapeutic agent in the combination therapy is a fibrate.
  • Fibric acid derivatives are a class of medications that lower blood triglyceride levels. Fibrates lower blood triglyceride levels by reducing the liver's production of VLDL and by speeding up the removal of triglycerides from the blood. Fibrates are also modestly effective in increasing blood HDL cholesterol levels; however, fibrates are not effective in lowering LDL cholesterol.
  • Exemplary fibrates include, but are not limited to, Bezafibrate (e.g. Bezalip®), Ciprofibrate (e.g. Modalim®), Clofibrate, Gemfibrozil (e.g. Lopid®) and Fenofibrate (e.g. TriCor®).
  • the therapeutic agent in the combination therapy is a bile acid resin.
  • Bile acid resins also known as bile acid sequesterants, are mainly used to treat patients with moderately elevated LDL- cholesterol and when cholesterol-lowering drug therapy is necessary in young adult men and premenopausal women. They are also sometimes combined with other cholesterol-lowering drugs like "statins" to decrease very high levels of cholesterol.
  • Exemplary bile acid resins include, but are not limited to, Cholestyramine, Colestipol (Colestid), and Cholsevelam (Welchol).
  • the therapeutic agent in the combination therapy is a cholesterol absorption inhibitor.
  • Ezetimibe (Zetia®, Ezetrol®, Ezemibe®) is the only prescription drug currently in this class. This drug prevents dietary cholesterol from being absorbed from the small intestine and entering the blood, thus lowering blood cholesterol levels.
  • Synergistic compositions comprising a cholesterol absorption inhibitor and a layered phyllosilicate material described herein is particularly contemplated.
  • salicylic acid Aspirin has been shown to have a protective effect against heart attacks in patients with clogged blood vessels, and can also be used in a composition according to the present invention.
  • the cholesterol-reducing mechanism is believed to be based on the acidic properties of aspirin, and as such the acid deconjugates the bilexholesterol complex (or cholesterol micelle), reducing bioavailability.
  • the therapeutic agent in the combination therapy is a phytosterol.
  • Phytosterols also known as plant sterols or stanols, are lipids having chemical structures similar to cholesterol, which are present in all plants including but not limited to vegetables, fruits, and grains, particularly in nuts, seeds, and plant oils.
  • Phytosterols inhibit intestinal cholesterol absorption, thereby lowering plasma total and low-density lipoprotein (LDL) cholesterol levels.
  • Daily consumption of about one to two grams of phytosterols reduces the risk for cardiovascular disease by about 25 to about 28% without causing any adverse effects.
  • the therapeutic agent in the combination therapy is a polysaccharide including but not limited to, alginate, pectin, gellan gum, xanthan gum and zooglan.
  • Alginates, pectins and modifications thereof are reported to interact with dietary cholesterol and affect its absorption and excretion (see U.S. Patent Nos. 5, 141,927; 5,597,810; 7,026,302, Japanese Patent No. 09235234, and Kimura et al., J. Ethnopharmacol, 54(1 ):47 54 (1996), the disclosures of which are incorporated herein by reference in their entireties).
  • the therapeutic agent in the combination therapy is Lecithin (CAS # 8002-43-5).
  • Leithin is usually used as a synonym for phosphatidylcholine, a phospholipid which is the major component of a phosphatide fraction isolated from egg yolk or soy beans.
  • Lecithin is commercially available in high purity as a food supplement and for medical uses. For example, Lecithin 19 Grain is sold over the counter and has been reported to reduce cholesterol.
  • nutraceuticals are also contemplated for use in the combination therapy.
  • the nutraceutical is an extract of green tea.
  • Green tea contains volatile oils, vitamins, minerals, and caffeine, but the primary constituents of interest are the polyphenols, particularly the catechin called epigallocatechin gallate (EGCG).
  • EGCG epigallocatechin gallate
  • the polyphenols are believed to be responsible for most of green tea's roles in promoting good health.
  • Green tea has been shown to mildly lower total cholesterol levels and improve the cholesterol profile (decreasing LDL cholesterol and increasing HDL cholesterol) in most, (Kono et al., Japan. Prev Med., 21:526-31, 1992; Yamaguchi et al., Nip Yak Zas., 97:329- 37, 1991; Sagesaka-Mitane et al., Chem Pharm Bull., ;38:790-3, 1990; Stensvold et al., Prev Med., 21:546-53, 1992) but not all (Tsubono et al., Ann Epidemiol., 7:280-4, 1997) studies. Green tea may also promote cardiovascular health by making platelets in the blood less sticky.
  • the nutraceutical is a dietary supplement selected from the group consisting of Cholest- ArrestTM (500 mg garlic and 200 mg lecithin); CholestawayTM (700 mg Calcium carbonate, 170 mg magnesium oxide 50 ⁇ g chromium picolinate), Cholest- OffTM (900 mg of plant sterols/stanols), Guggul Bolic (750mg of gugulipid (Commiphora mukul gum resin), and Kyolic® (600 mg aged garlic extract and 380 mg lecithin).
  • Cholest- ArrestTM 500 mg garlic and 200 mg lecithin
  • CholestawayTM 700 mg Calcium carbonate, 170 mg magnesium oxide 50 ⁇ g chromium picolinate
  • Cholest- OffTM 900 mg of plant sterols/stanols
  • Guggul Bolic 750mg of gugulipid (Commiphora mukul gum resin)
  • Kyolic® 600 mg aged garlic extract and 380 mg lecithin.
  • a composition comprising a layered phyllosilicate material alone or in combination as described herein may be so arranged, e.g., in a kit or package or unit dose, to permit co- administration with one or more other therapeutic agents, but the layered phyllosilicate material composition and the agent are not in admixture.
  • the layered phyllosilicate material composition and the agent are in admixture.
  • the two components to the kit/unit dose are packaged with instructions for administering the two agents to a mammalian subject for treatment of one of the above- indicated disorders and diseases.
  • the present Example demonstrates the ion exchange process of smectite clay from a Ca form or Na/Ca mixed forms to Na-rich smectite clay.
  • Raw smectite clay was dispersed into water to make a 3 wt% clay slurry.
  • This clay has a Na content of 0.20 wt% and Ca content of 2.10 wt%.
  • the elemental analysis was measured by an X-ray fluorescence method. The mixture was mixed thoroughly with a mechanical mixer. The pH value of the starting clay slurry is 7-8.
  • An ion exchange resin such as Amberlite 200C Na, is available from Rohm & Hass packed in a glass column with a 2-in diameter and a 20-in length. A liquid pump was used to pump the clay slurry through the column at 20 ml/min.
  • the ion exchanged clay is called El-Na-Clay. This clay had a basal spacing of 13 A.
  • Example 2 Preparation of a hydrogen protonated layered phyllosilicate material.
  • the present Example demonstrates the ion exchange process to convert a sodium smectite clay to a hydrogen protonated smectite clay (i.e., Compound A).
  • Smectite clay comprising about 80% sodium and about 20% calcium/magnesium as exchangeable ions was processed to a particle size of approximately 74 ⁇ m and purified via the process described in U.S. Patent No. 6,050,509. After purification, the smectite clay comprised predominantly sodium ions.
  • the purified sodium exchanged clay was dispersed into filtered DI water to make a 3 wt% clay slurry.
  • the mixture was mixed thoroughly with a Silverson honiogenizer.
  • the pH value of the starting clay slurry was about 10.
  • the clay slurry was slowly mixed using a 3-inch dispersion blade at 800 rpm while a liquid pump was used to pump the clay slurry through two resin packed columns at 20 ml/min.
  • the pH of the clay slurry was 2.3 after passing through the second column.
  • the clay was then gamma irradiated to prevent bacterial contamination.
  • the resulting hydrogen protonated smectite clay was designated as Compound A and was used in some of the in vivo assays described herein.
  • Compound A was measured for particle size distribution using the Coulter LS230 particle size analyzer. Circulation speed was set at 75%. Distribution was calculated using the Fraunhofer model. IA 1 : 10 dilution of Compound A was made using a blender at 7,000 rpm for 5 minutes. The particle size measurements for Compound A were as follows:
  • the present Example demonstrates the formation of protonated Octadecyl ammonium-treated smectite clay with Octadecyl ammonium acetate from the ion exchanged Na-smectite clay (El-Na-clay) of Example 1.
  • 100-g of sodium smectite clay El -Na-clay was dispersed into 3000 ml water through a mechanical mixer. This clay slurry was heated to 80 0 C. 41.5 g of Octadecyl ammonium acetate from KAO Chemicals was added into the clay slurry. The clay showed excellent flocculation after the addition of the Octadecyl ammonium acetate.
  • the pH of the clay reaction slurry was about 4.
  • the clay was filtered with regular quantitative filter paper with the assistance of a mechanical vacuum pump. Then, the clay was dried in an oven over night at 80 0 C and ground to pass through a 300-mesh screen as a fine powder.
  • This modified clay was called E2-ODA-Clay.
  • the present Example demonstrates the formation of protonated Octadecyl ammonium-treated smectite clay with a solution of Octadecyl ammonium ions in dilute HCl. (E3-ODA-Clay). This sample was measured by powder X-ray diffraction to determine the clay basal spacing after ion exchange. The result is listed in Table- 1.
  • Example 5 Preparation of protonated Lecithin phyllosilicate material. ⁇ 00149] The present Example demonstrates the formation of protonated Lecithin (CAS # 8002-43-5) treated smectite clay with a solution of Lecithin in dilute HCl (E3-ODS-Clay) (i.e., Compound B).
  • Compound B was further measured for particle size distribution using the Coulter LS230 particle size analyzer. Circulation speed was set at 75%. Distribution was calculated using the Fraunhofer model. 1 wt% solutions were made of Compound B using a blender at 7,000 rpm for 5 minutes. The particle size measurements of Compound B were as follows:
  • the present Example demonstrates the preparation a layered phyllosilicate material with surface acid treatment (i.e., Compound C).
  • Bentonite was crushed, granulated and then sprayed with water as it travelled along a belt towards the extruder.
  • the extruded bentonite was then sprayed with 75% H 2 SO 4 which formed salts with the interlayer cations.
  • the bentonite was then extruded once again to a smaller size.
  • the acidified clay particles continued along the belt towards the activation tank.
  • the tank was simultaneously filled with bentonite and acid for two hours. Steam was added to the H 2 SO 4 acid stream prior to reaching the tank to reduce the concentration to 35% and to reach a temperature of 90 0 C, which was maintained throughout the acid activation process.
  • wash A and wash B the freshly activated bentonite was subjected to two washing steps (i.e., wash A and wash B) to remove salts produced by the acid treatment.
  • wash A 4% H 2 SO4 at 9O 0 C was circulated around the tank while the acid concentration of wash B was 2%.
  • wash B the tank was drained and the activated bentonite extrudates were shovelled from the tank to a stockpile.
  • the activated bentonite extrudates were later subjected to the drier where the moisture is reduced and are broken into granules.
  • the resulting nanobentonite compound with surface acid treatment was designated as Compound C and was used in some of the in vivo assays described herein.
  • Compound C was measured for particle size distribution using the Coulter LS230 particle size analyzer. Circulation speed was set at 75%. Distribution was calculated using the Fraunhofer model. 1 wt% solutions were made of Compound C using a blender at 7,000 rpm for 5 minutes. The particle size measurements of Compound C were as follows:
  • the present Example describes the preparation of layered phyllosilicate materials designated herein as Compound G, Compound H, Compound I, Compound J, Compound K, Compound L, and Compound M.
  • the purified sodium exchanged clay was dispersed into filtered DI water to make a 2.7 wt% clay slurry.
  • the mixture was mixed thoroughly with a Silverson homogenizer.
  • the pH value of the starting clay slurry was about 10.
  • An hydrogen ion exchange resin, Amberlite FPC23 H (Rohm & Hass) was packed into two glass columns with a 2-in diameter and a 20-in length; one inch of space was left at the top of each column to promote flowability of the beads.
  • the clay slurry was slowly mixed using a 3-inch dispersion blade at 800 rpm while a liquid pump was used to pump the clay slurry through two resin packed columns at 20 ml/min.
  • the clay was then gamma irradiated to prevent bacterial contamination.
  • the resulting clay was designated as Compound G.
  • Compound H A smectite clay comprising about 70% sodium and about 30% calcium/magnesium as exchangeable ions was processed to a particle size of approximately 74 ⁇ m and purified via the process described in U.S. Patent No. 6,050,509. After purification, the smectite clay comprised predominantly sodium ions.
  • the purified sodium exchanged clay was dispersed into filtered DI water to make a 2.6 wt% clay slurry.
  • the mixture was mixed thoroughly with a Silverson homogenizer.
  • the pH value of the starting clay slurry was about 10.
  • An hydrogen ion exchange resin, Amberlite FPC23 H (Rohm & Hass) was packed into two glass columns with a 2-in diameter and a 20-in length; one inch of space was left at the top of each column to promote flowability of the beads.
  • the clay slurry was slowly mixed using a 3-inch dispersion blade at 800 rpm while a liquid pump was used to pump the clay slurry through two resin packed columns at 20 ml/min.
  • the clay was then gamma irradiated to prevent bacterial contamination.
  • the resulting clay was designated as Compound H.
  • Compound I Preparation of Compound I: A smectite clay comprising about 80% sodium and about 20% calcium/magnesium as exchangeable ions was processed to a particle size of approximately 74 ⁇ m and purified via the process described in U.S. Patent No. 6,050,509. After purification, the smectite clay comprised predominantly sodium ions. The clay was then gamma irradiated to prevent bacterial contamination. The resulting clay was designated as Compound I.
  • a smectite clay comprising about 80% sodium and about 20% calcium/magnesium as exchangeable ions was processed to a particle size of approximately 74 ⁇ m and purified via the process described in U.S. Patent No. 6,050,509. After purification, the smectite clay comprised predominantly sodium ions.
  • a 2.8 wt% mixture of the purified smectite clay and filtered deionized water was made using a blender at 7000 rpm for 3-5 minutes. The resulting clay slurry was then treated with 6N HCl drop wise until a pH of 2.2 was obtained. The clay was then gamma irradiated to prevent bacterial contamination.
  • the resulting surface acid treatment smectite clay was designated as Compound J.
  • Compound K A smectite clay comprising about 80% sodium and about 20% calcium/magnesium as exchangeable ions was processed to a particle size of approximately 74 ⁇ m and purified via the process described in U.S. Patent No. 6,050,509. After purification, the smectite clay comprised predominantly sodium ions.
  • the purified sodium exchanged clay was dispersed into filtered Dl water to make a 3 wt% clay slurry.
  • the mixture was mixed thoroughly with a Silverson homogenizer.
  • the pH value of the starting clay slurry was about 10.
  • An hydrogen ion exchange resin, Amberlite FPC23 H (Rohm & Hass) was packed into two glass columns with a 2-in diameter and a 20-in length; one inch of space was left at the top of each column to promote flowability of the beads.
  • the clay slurry was slowly mixed using a 3-inch dispersion blade at 800 rpm while a liquid pump was used to pump the clay slurry through two resin packed columns at 20 ml/min.
  • the pH of the clay slurry was 2.3 after passing through the second column.
  • the slurry was then treated with NaOH drop wise until a pH of 10 was obtained.
  • Final mixture of the slurry 2.7 wt%.
  • the clay was then gamma irradiated to prevent bacterial contamination.
  • the resulting clay was designated as Compound K.
  • Compound L A smectite clay comprising about 70% sodium and about 30% calcium/magnesium as exchangeable ions was processed to a particle size of approximately 74 ⁇ m and purified via the process described in U.S. Patent No. 6,050,509. After purification, the smectite clay comprised predominantly sodium ions. The clay was then gamma irradiated to prevent bacterial contamination. The resulting sodium ion exchanged claim was designated as Compound L.
  • Compound M A smectite clay comprising about 5% sodium and about 95% calcium/magnesium as exchangeable ions was processed to a particle size of approximately 74 ⁇ m and purified via the process described in U.S. Patent No. 6,050,509. After purification, the smectite clay comprised predominantly sodium ions. The clay was then gamma irradiated to prevent bacterial contamination. The resulting sodium ion exchanged claim was designated as Compound M.
  • Example 8 Layered Phyllosilicate Material Reduced Cholesterol in vitro
  • the present Example was performed to determine the effect of various phyllosilicate materials on the adsorption of cholesterol from an aqueous solution.
  • Cholesterol powder was obtained from Aldrich Chemical Company (Milwaukee, WI).
  • a stock solution of cholesterol was prepared by dissolving the pure crystals in acetonitrile and then injecting an amount into purified water (pH 6.8) to yield a solution concentration of 4 mg/mL. The exact concentration of the stock solution was verified by liquid chromatography.
  • Each isotherm consisted of triplicate 5 mL aqueous samples of Cholesterol made from dilutions of the stock to yield approximate concentrations of 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0 ug/mL and placed in sterile 17 x 100 mm polypropylene centrifuge test tubes.
  • a suspension of layered phyllosilicate material was prepared by weighing 10 mg of layered phyllosilicate material into a 25 mL Erlenmeyer flask and pipetting the appropriate volume of water in the flask to make the clay concentration 1 mg/mL. A stir bar was added to the flask, and the suspension was mixed to keep the slurry homogeneous.
  • 50 uL (containing 50 ug of clay) was pipetted out with an autopipetor and added to each 5 mL test sample.
  • Four controls were also prepared: a water control containing no cholesterol, cholesterol controls containing 0.5 and 4.0 ug/ mL cholesterol, and a control containing 5 mL water and 50 ⁇ g of clay. Samples were capped and mixed by shaking at 1000 rpm at 37 0 C for 2 hours.
  • Example 9 Layered Phyllosilicate Material Reduces Hypercholesteremia in an Animal Model
  • the present Example will be performed to determine the effect of various layered phyllosilicate materials on plasma lipids in rabbits.
  • Rabbits are appropriate animals for the study of the effects of lipid-lowering agents because diet can be manipulated to induce hypercholesterolaemia (Kroon et al., Atherosclerosis, 44:41-48, 1982; Prior et al., Archives of Pathology, 71:82-94, 1961; Kolodgie et al., Arterioscler Thromb Vase Biol, 16:1454-1464, 1996).
  • the cholesterol-fed rabbit model has previously been used to demonstrate the lipid-lowering effects of statins (Nielsen et al. Pharmacol Toxicol, 72(3): 148-151, 1993).
  • the fat/cholesterol-enriched diet will consist of Purina rabbit chow supplemented with 14.0% (weight/volume) coconut oil and 0.50% (weight/volume) cholesterol.
  • Group A layered phyllosilicate material (nanobentonite dispersed in deionized water)
  • Group B layered phyllosilicate material nanobentonite with surface acid treatment
  • Group C layered phyllosilicate material (nanobentonite with surface modified with lecithin) will be housed in individual cages in a room with constant humidity and temperature (22 0 C) under a 12 hour light-dark cycle, and fed a standard diet for 7 days.
  • animals After 7 days, animals will be fed 10 g of a regular chow diet plus 100 g of the same diet supplemented with 0.5% (w/v) cholesterol and 14.0% (w/v) coconut oil for 28 days.
  • the final diet administered to these rabbits (following dilution of 100 g of high fat/cholesterol diet with 1O g of regular chow) consistent of 0.45% (w/v) cholesterol and 12.75% (w/v) coconut oil.
  • the animals Following 28 days on this diet, the animals will be assigned based on their 16 hour post- meal plasma cholesterol and triglyceride concentrations, into five groups of six animals each with no statistically significant differences between total plasma cholesterol and triglyceride concentrations.
  • Whole blood will be collected (3 ml) prior to and 28 days after initiation of treatment for plasma lipid determinations.
  • Plasma total cholesterol and triglyceride concentrations will be directly quantified using enzymatic kits (Sigma Aldrich).
  • HDL cholesterol concentrations will be determined using the dextran sulfate-Mg 2+ precipitation method as developed by Warnick et ciL (Clin Chem., 28:1379-1388, 1982).
  • the Friedewald equation for determining LDL cholesterol can not be used in this rabbit fed model (Friedewald et al., Clin Chem., 18:499- 502, 1972).
  • measurement of apoB cholesterol (which takes into account LDL cholesterol) concentrations will be determined by subtracting HDL cholesterol concentrations from total cholesterol concentrations.
  • Results will be expressed as mean ⁇ standard error of the mean (SEM).
  • Statistical analyses will be conducted using an analysis of variance (PCANOVA; Human Dynamic Systems) and assuming unequal variance (Newman Keuls post-hoc test; we assumed unequal variance).
  • Variables compared among treatment groups include, weight gain, total plasma cholesterol, total plasma triglyceride, HDL-eholesterol and ApoB cholesterol. A p-value of less than 0.05 will indicate a significant difference between treated and untreated groups.
  • Example 10 Layered Phyllosilicate Material Reduces Hypercholesteremia in another Animal Model
  • Example 11 Layered Phyllosilicate Material Reduced Hypercholesteremia in an Animal
  • the final diet administered to these rabbits (following dilution of 100 g of high fat/cholesterol diet with 10 g of regular chow) consistent of 0.45% (w/v) cholesterol and 12.75% (w/v) coconut oil. Following 28 days on this diet, the animals were assigned based on their 16 h post- meal plasma cholesterol and triglyceride concentrations, into five groups with no statistically significant differences between total plasma cholesterol and triglyceride concentrations.
  • the total plasma cholesterol, ApoB, HDL and triglyceride concentrations of the subjects prior to drug treatment is set forth in Figures 1-4, respectively.
  • Plasma total cholesterol and triglyceride concentrations were directly quantified using enzymatic kits (Sigma Aldrich).
  • HDL- cholesterol concentrations were determined using the dextran sulfate-Mg 2+ precipitation method as developed by Warnick et al. (9).
  • the Friedewald equation for determining LDL cholesterol could not be used in this rabbit fed model (10).
  • measurement of apoB cholesterol (which takes into account LDL- cholesterol) concentrations were determined by subtracting HDL-cholesterol concentrations from total cholesterol concentrations.
  • Choi cholesterol
  • HDL high-density lipoproteins
  • ApoB Apo lipoprotein B
  • TG triglycerides
  • 'high cholesterol diet consists of 0.45% w/v cholesterol plus 12.75% w/v coconut oil
  • Example 12 Layered Phyllosilicate Material Reduced Hypercholesteremia in a Rat Model
  • ezetimibe formulation Commercially available ezetimibe tablets were crushed and suspended in double distilled water to reach final ezetimibe concentration of 5 mg/ml. The suspension was briefly vortexed and then stirred using a magnetic stirrer for about 1 hour until ready for administration.
  • the right external jugular vein was cannulated with a two-part catheter consisting of PE 50 connected to a short length of 0.02- inch silastic tubing inserted 3.2 cm past the clavicle (Hauss et al., Contemp Top Lab Anim ScL, 37(3):56-58 1998).
  • the jugular cannula was tunneled beneath the skin and exteriorized through a small stab wound in the back of the neck.
  • the animals were outfitted with jacket- and-tether assemblies and placed in metabolism cages for the duration of the study.
  • Treatment groups 1-3 were designed to demonstrate that the animal model is working as expected and to show the effects of Sitostanol and Zetia on the reduction of cholesterol absorption as compared to the vehicle controls.
  • Treatment groups 4-14 were designed to demonstrate the effects of various layered phyllosilicate materials on the reduction of cholesterol in a severe dyslipidemic model. All of test Compounds A, G, H, I, J, K, L or M were given as a separate slurry to the animal by oral gavage.
  • Results indicated that Compounds A, G, H , I and M were successful in reducing cholesterol absorption in the rat compared to the control. See Table 5 below and Figure 9.
  • Table 5 AUC calculated from plasma concentration-time profiles of cholesterol when administered with different layered phyllosilicate material compounds.
  • % control group means % reduction in cholesterol compared to the control. For example, for ezetimibe. the quantity of adsorbed cholesterol was 8.6 % compared to the control. Therefore, administration of ezetimibe resulted in 91.4% lower radioactive labeled cholesterol measured in the blood plasma.
  • adsorption of bile acids, fatty acids, monoglycerides or other constituents of cholesterol-containing mixed micelles to the layered phyllosilicate material or alteration in the lipolysis process of co-administered lipid-based formulation is also supported by the in vitro effects of food grade silicon dioxide on the adsorption of bile salts (Peluso et al., J. Nutr., 124:853-860, 1994) and the adsorption of bile salts by bismuthsubsalicylate and montmorillonite, the active components in Pepto-Bismol® (Kocoshis et al., Dig. Dis. ScL, 24:1148-1152, 1984).
  • Figure 12 shows the dependence of exposure to radioactive cholesterol (AUCo 4 8 h) on the dose of Compound A administered at either 0 mg/kg (control), 20 mg/kg, 50 mg/kg, and 100 mg/kg.
  • Example 13 Layered Phyllosilicate Material Reduces Plasma Cholesterol Concentrations in ApoE-Deficient Mice

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Les phyllosilicates en couches sont utiles pour adsorber le cholestérol et/or se lier à celui-ci, et, par conséquent, pour réduire le cholestérol sanguin chez un patient. L'invention concerne un procédé visant à réduire l'hypercholestérolémie chez un mammifère, par l'administration audit mammifère d'une matière de phyllosilicate en couches protonée et au moins partiellement exfoliée, seule et en combinaison avec d'autres agents hypocholestérolémiants en quantité efficace pour réduire l'hypercholestérolémie chez ce mammifère.
PCT/US2008/064351 2007-05-23 2008-05-21 Phyllosilicates en couches interagissant avec le cholestérol et procédés visant à réduire l'hypercholestérolémie chez un mammifère WO2008147807A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DK08780675.8T DK2167069T3 (da) 2007-05-23 2008-05-21 Cholesterol-interagerende lagdelte phyllosilikater og fremgangsmåder til at reducere hypercholesterolæmi hos et pattedyr
EP08780675A EP2167069B1 (fr) 2007-05-23 2008-05-21 Phyllosilicates en couches interagissant avec le cholestérol et procédés visant à réduire l'hypercholestérolémie chez un mammifère
PL08780675T PL2167069T3 (pl) 2007-05-23 2008-05-21 Krzemiany warstwowe oddziałujące z cholesterolem oraz sposoby zmniejszania hipercholesterolemii u ssaka
CA002688111A CA2688111A1 (fr) 2007-05-23 2008-05-21 Phyllosilicates en couches interagissant avec le cholesterol et procedes visant a reduire l'hypercholesterolemie chez un mammifere
AT08780675T ATE530178T1 (de) 2007-05-23 2008-05-21 Mit cholesterin interagierende phyllosilikate und verfahren zur reduktion von hypercholesterinämie bei einem säuger

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96655707P 2007-05-23 2007-05-23
US60/966,577 2007-05-23
US3193108P 2008-02-27 2008-02-27
US61/031,931 2008-02-27

Publications (2)

Publication Number Publication Date
WO2008147807A2 true WO2008147807A2 (fr) 2008-12-04
WO2008147807A3 WO2008147807A3 (fr) 2009-03-19

Family

ID=39811672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064351 WO2008147807A2 (fr) 2007-05-23 2008-05-21 Phyllosilicates en couches interagissant avec le cholestérol et procédés visant à réduire l'hypercholestérolémie chez un mammifère

Country Status (8)

Country Link
US (2) US8481084B2 (fr)
EP (2) EP2431043A1 (fr)
AT (1) ATE530178T1 (fr)
CA (1) CA2688111A1 (fr)
DK (1) DK2167069T3 (fr)
ES (1) ES2372652T3 (fr)
PL (1) PL2167069T3 (fr)
WO (1) WO2008147807A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3391754A1 (fr) * 2017-04-21 2018-10-24 Tolsa, S.A. Additif alimentaire pour animaux, procédé de préparation et utilisation en tant qu'agent prophylactique contre l'acidose du rumen

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120058157A1 (en) * 2007-05-23 2012-03-08 Amcol International Corporation Methods of Treating Cardiovascular Disorders Associated with Atherosclerosis
US8936817B2 (en) * 2010-05-05 2015-01-20 Ayurvedic-Life International, Llc Preparation for weight loss management
CA2706270C (fr) * 2010-06-03 2020-01-07 Accucaps Industries Limited Formulations pharmaceutiques de statines et d'acides gras omega-3 pour encapsulation
CA3065589C (fr) 2010-06-03 2022-04-26 Catalent Ontario Limited Capsules multiphases de gel mou, appareil et procede pour celles-ci
WO2012017321A2 (fr) * 2010-07-02 2012-02-09 Solvotrin Therapeutics Ltd. Traitement de la dyslipidémie
US20130331452A1 (en) * 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
RU2591079C2 (ru) * 2014-12-10 2016-07-10 Александр Владимирович Диковский Фармацевтическая композиция статинов с пребиотиком для терапии гиперхолестеринемии и гиперлипидимии
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN105248854A (zh) * 2015-11-06 2016-01-20 安徽省田丰牧业科技有限公司 反刍动物长途运输应激反应制剂及其使用方法
WO2019136274A1 (fr) * 2018-01-04 2019-07-11 Pure Care Pro Llc Produits combinés naturels et méthodes de régulation du cholestérol sanguin total

Citations (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US4096278A (en) 1976-07-01 1978-06-20 Andre Queuille Organic derivatives of montmorillonite for treating lipid disturbances
US4180566A (en) 1978-05-15 1979-12-25 W. R. Grace & Co. Silica gel method of reducing blood lipid concentration
US4211679A (en) 1978-09-28 1980-07-08 General Electric Company Organoboron plasticized polycarbonate composition
US4287200A (en) 1978-08-04 1981-09-01 Takeda Chemical Industries, Ltd. Thiazolidine derivatives
US4613593A (en) 1983-12-26 1986-09-23 Eisai Co., Ltd. Therapeutic and preventive agent containing dolichol
US4689344A (en) 1981-12-15 1987-08-25 Epis S.A. Long-chain α,ω-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS62223108A (ja) 1986-03-25 1987-10-01 Daito Kasei Kogyo Kk キトサンで被覆した化粧用顔料およびその製造方法
US4711896A (en) 1984-06-22 1987-12-08 Epis S.A. α, ω-dicarboxylic acids and medicaments which contain these compounds
EP0291960A2 (fr) 1987-05-19 1988-11-23 Yakurigaku Chuo Kenkyusho Préparation à base de silicate d'alumine synthétique
US4800878A (en) 1987-08-26 1989-01-31 Becton, Dickinson And Company Electrosurgical knife with visual alarm
US5102948A (en) 1989-05-19 1992-04-07 Ube Industries, Ltd. Polyamide composite material and method for preparing the same
US5112804A (en) 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5491171A (en) 1991-11-08 1996-02-13 Kyoto Pharmaceutical Industries, Ltd. Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
EP0778027A2 (fr) 1995-12-04 1997-06-11 Helmut Univ.-Prof. Dr. Wachter Utilisation de silice pour la préparation de médicaments
US5756344A (en) 1990-07-18 1998-05-26 Takeda Chemical Industries, Ltd. DNA coding for a human vasoconstrictive peptide and use thereof
US5756544A (en) 1995-03-24 1998-05-26 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US5759563A (en) 1994-04-08 1998-06-02 Atrix Laboratories, Inc. Liquid delivery compositions
WO1998030530A1 (fr) 1997-01-07 1998-07-16 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Acides carboxyliques et leurs derives, et compositions pharmaceutiques les contenant
US5853886A (en) 1996-06-17 1998-12-29 Claytec, Inc. Hybrid nanocomposites comprising layered inorganic material and methods of preparation
WO1999000116A2 (fr) 1997-06-26 1999-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Acides carboxyliques, leurs derives, et compositions pharmaceutiques les contenant
US5919474A (en) 1997-10-28 1999-07-06 Vivus, Inc. Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith
US5925629A (en) 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
EP0985411A1 (fr) 1998-09-02 2000-03-15 McNEIL-PPC, INC. Esters stéroliques en forme galénique solide sous forme de comprimé
US6050509A (en) 1998-03-18 2000-04-18 Amcol International Corporation Method of manufacturing polymer-grade clay for use in nanocomposites
US6165440A (en) 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US6248760B1 (en) 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
US6287576B1 (en) 1997-11-17 2001-09-11 Zakrytoe Aktsionernoe Obschestvo Nauchno-Proizvodstvennaya Firma “NOV” Biostimulating agent
US6355248B1 (en) 1997-01-02 2002-03-12 Thomas Jefferson University Method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent
US6383478B1 (en) 1999-04-22 2002-05-07 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
US6391318B1 (en) 1995-12-07 2002-05-21 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Vaccine compositions including chitosan for intranasal administration and use thereof
US6432200B2 (en) 1998-08-28 2002-08-13 Lilly Technologies, Inc. Silver film incorporating protective insoluble metallic salt precipitate
US6443989B1 (en) 2000-12-04 2002-09-03 Roger P. Jackson Posterior expandable fusion cage
US6482439B2 (en) 1999-12-29 2002-11-19 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
US6506799B1 (en) 1999-04-01 2003-01-14 Esperion Therapeutics, Inc. Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
KR20030076536A (ko) 2003-09-03 2003-09-26 (주)서봉바이오베스텍 비만억제제로서의 게르마늄 복합광물과 그 용도
US6706289B2 (en) 2000-10-31 2004-03-16 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
US6730334B2 (en) 2001-01-19 2004-05-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US6797704B2 (en) 2000-10-06 2004-09-28 The Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
US20050058701A1 (en) 2003-01-29 2005-03-17 Yossi Gross Active drug delivery in the gastrointestinal tract
US20050058603A1 (en) 2003-05-02 2005-03-17 Case Western Reserve University Drug delivery system based on polymer nanoshells
US20050089572A1 (en) 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
US6915424B1 (en) 2000-06-01 2005-07-05 Intel Corporation Method for theft detection and notification via a network
US20050152965A1 (en) 2001-04-25 2005-07-14 Betageri Guru V. Coated drug delivery formulations
US20050209345A1 (en) 2001-06-15 2005-09-22 Charman William N Lymphatic drug delivery system
US20050220754A1 (en) 1999-06-02 2005-10-06 Biotech Australia Pty. Ltd. Vitamin directed targeting therapy
US20050249774A1 (en) 1997-06-11 2005-11-10 Pauletti Giovanni M Coated vaginal device for delivery of anti-migraine and anti-nausea drugs and a method for treatment of migraine and nausea
US20050249798A1 (en) 2002-06-18 2005-11-10 Euro-Celtique, S.A. Gastroretentive drug delivery system comprising an extruded hydratable polymer
US20050260276A1 (en) 2004-05-19 2005-11-24 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
US20050266090A1 (en) 2003-04-29 2005-12-01 Ales Prokop Nanoparticular targeting and therapy
US20060034925A1 (en) 2004-04-02 2006-02-16 Au Jessie L Tumor targeting drug-loaded particles
US20060057206A1 (en) 2004-08-19 2006-03-16 Wong Patrick S Controlled release nanoparticle active agent formulation dosage forms and methods
US20060105049A1 (en) 2004-11-12 2006-05-18 Valorisation Recherche Hscm & Universite De Montreal Folic acid-chitosan-DNA nanoparticles
US20060149392A1 (en) 2004-12-07 2006-07-06 Kuo-Huang Hsieh Biomaterials for guided tissue regeneration and drug delivery
US20060188543A1 (en) 2005-01-31 2006-08-24 Si-Shen Feng Nanoparticle coating for drug delivery
US20060193787A1 (en) 2005-01-31 2006-08-31 Si-Shen Feng Nanoparticle-based drug delivery system
US20070003610A1 (en) 2001-08-13 2007-01-04 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20070026048A1 (en) 2001-02-13 2007-02-01 Robert Greenberg Implantable drug delivery device
US20070031340A1 (en) 2001-05-24 2007-02-08 Hale Ron L Thin-film drug delivery article and method of use
US20070036278A1 (en) 2004-06-02 2007-02-15 Audiopoint, Inc. System, method and computer program product for interactive voice notification and product registration
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US20070059327A2 (en) 1998-01-15 2007-03-15 Wyeth Streptococcus equi compositions and methods of use
WO2007038596A2 (fr) 2005-09-28 2007-04-05 Wyeth Additifs nutritionnels a base de phytosterol

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294846A (en) 1979-09-21 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and products of preparation
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4420491A (en) 1980-05-28 1983-12-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4514510A (en) * 1983-09-08 1985-04-30 American Colloid Company Hydrogen enriched water swellable clay having reduced acid demand and stable at low pH
US4582915A (en) 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US5597810A (en) 1984-12-27 1997-01-28 Hoffman; Allan S. Method for reducing absorption of undesired lipids in the gastrointestinal tract
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
JP2851627B2 (ja) 1987-10-15 1999-01-27 シンテックス（ユー・エス・エイ）インコーポレイテッド 粉末形態ポリプペチド類の経鼻投与
ATE116859T1 (de) 1990-07-04 1995-01-15 Marcin Krotkiewski Blutdrucksenkendes präparat.
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
JP3878239B2 (ja) 1996-02-29 2007-02-07 マルハ株式会社 循環器系疾患予防治療剤
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
AUPO758297A0 (en) * 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
MXPA01000271A (es) * 1998-07-13 2002-10-17 Expression Genetics Inc Analogo de poliester de poli-lisina como un portador para el suministro de genes, soluble, biodegradable.
US6462029B1 (en) 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
PL357533A1 (en) 2000-03-03 2004-07-26 Plus Chemicals, S.A. A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
KR100596257B1 (ko) * 2001-01-26 2006-07-03 쉐링 코포레이션 스테롤 흡수 억제제를 포함하는 조성물, 및 페록시솜 증식인자-활성화 수용체 활성화제와 스테롤 흡수 억제제를 포함하는 조성물 및 조합물
US20050181015A1 (en) * 2004-02-12 2005-08-18 Sheng-Ping (Samuel) Zhong Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses

Patent Citations (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US4096278A (en) 1976-07-01 1978-06-20 Andre Queuille Organic derivatives of montmorillonite for treating lipid disturbances
US4180566A (en) 1978-05-15 1979-12-25 W. R. Grace & Co. Silica gel method of reducing blood lipid concentration
US4287200A (en) 1978-08-04 1981-09-01 Takeda Chemical Industries, Ltd. Thiazolidine derivatives
US4211679A (en) 1978-09-28 1980-07-08 General Electric Company Organoboron plasticized polycarbonate composition
US4689344A (en) 1981-12-15 1987-08-25 Epis S.A. Long-chain α,ω-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US4613593A (en) 1983-12-26 1986-09-23 Eisai Co., Ltd. Therapeutic and preventive agent containing dolichol
US4711896A (en) 1984-06-22 1987-12-08 Epis S.A. α, ω-dicarboxylic acids and medicaments which contain these compounds
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
JPS62223108A (ja) 1986-03-25 1987-10-01 Daito Kasei Kogyo Kk キトサンで被覆した化粧用顔料およびその製造方法
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5112804A (en) 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
EP0291960A2 (fr) 1987-05-19 1988-11-23 Yakurigaku Chuo Kenkyusho Préparation à base de silicate d'alumine synthétique
US4800878A (en) 1987-08-26 1989-01-31 Becton, Dickinson And Company Electrosurgical knife with visual alarm
US5102948A (en) 1989-05-19 1992-04-07 Ube Industries, Ltd. Polyamide composite material and method for preparing the same
US5756344A (en) 1990-07-18 1998-05-26 Takeda Chemical Industries, Ltd. DNA coding for a human vasoconstrictive peptide and use thereof
US5491171A (en) 1991-11-08 1996-02-13 Kyoto Pharmaceutical Industries, Ltd. Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5759563A (en) 1994-04-08 1998-06-02 Atrix Laboratories, Inc. Liquid delivery compositions
US5780044A (en) 1994-04-08 1998-07-14 Atrix Laboratories, Inc. Liquid delivery compositions
US5756544A (en) 1995-03-24 1998-05-26 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
EP0778027A2 (fr) 1995-12-04 1997-06-11 Helmut Univ.-Prof. Dr. Wachter Utilisation de silice pour la préparation de médicaments
US6391318B1 (en) 1995-12-07 2002-05-21 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Vaccine compositions including chitosan for intranasal administration and use thereof
US5853886A (en) 1996-06-17 1998-12-29 Claytec, Inc. Hybrid nanocomposites comprising layered inorganic material and methods of preparation
US6355248B1 (en) 1997-01-02 2002-03-12 Thomas Jefferson University Method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent
WO1998030530A1 (fr) 1997-01-07 1998-07-16 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Acides carboxyliques et leurs derives, et compositions pharmaceutiques les contenant
US20050249774A1 (en) 1997-06-11 2005-11-10 Pauletti Giovanni M Coated vaginal device for delivery of anti-migraine and anti-nausea drugs and a method for treatment of migraine and nausea
WO1999000116A2 (fr) 1997-06-26 1999-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Acides carboxyliques, leurs derives, et compositions pharmaceutiques les contenant
US6165440A (en) 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US5919474A (en) 1997-10-28 1999-07-06 Vivus, Inc. Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith
US5925629A (en) 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6287576B1 (en) 1997-11-17 2001-09-11 Zakrytoe Aktsionernoe Obschestvo Nauchno-Proizvodstvennaya Firma “NOV” Biostimulating agent
US20070059327A2 (en) 1998-01-15 2007-03-15 Wyeth Streptococcus equi compositions and methods of use
US6050509A (en) 1998-03-18 2000-04-18 Amcol International Corporation Method of manufacturing polymer-grade clay for use in nanocomposites
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6432200B2 (en) 1998-08-28 2002-08-13 Lilly Technologies, Inc. Silver film incorporating protective insoluble metallic salt precipitate
EP0985411A1 (fr) 1998-09-02 2000-03-15 McNEIL-PPC, INC. Esters stéroliques en forme galénique solide sous forme de comprimé
US6506799B1 (en) 1999-04-01 2003-01-14 Esperion Therapeutics, Inc. Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds
US6248760B1 (en) 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
US6383478B1 (en) 1999-04-22 2002-05-07 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
US20050220754A1 (en) 1999-06-02 2005-10-06 Biotech Australia Pty. Ltd. Vitamin directed targeting therapy
US6482439B2 (en) 1999-12-29 2002-11-19 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
US6915424B1 (en) 2000-06-01 2005-07-05 Intel Corporation Method for theft detection and notification via a network
US6797704B2 (en) 2000-10-06 2004-09-28 The Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
US6706289B2 (en) 2000-10-31 2004-03-16 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
US6443989B1 (en) 2000-12-04 2002-09-03 Roger P. Jackson Posterior expandable fusion cage
US6838528B2 (en) 2001-01-19 2005-01-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US6730334B2 (en) 2001-01-19 2004-05-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US20070026048A1 (en) 2001-02-13 2007-02-01 Robert Greenberg Implantable drug delivery device
US20050152965A1 (en) 2001-04-25 2005-07-14 Betageri Guru V. Coated drug delivery formulations
US20070031340A1 (en) 2001-05-24 2007-02-08 Hale Ron L Thin-film drug delivery article and method of use
US20050209345A1 (en) 2001-06-15 2005-09-22 Charman William N Lymphatic drug delivery system
US20070003610A1 (en) 2001-08-13 2007-01-04 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20050089572A1 (en) 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
US20050249798A1 (en) 2002-06-18 2005-11-10 Euro-Celtique, S.A. Gastroretentive drug delivery system comprising an extruded hydratable polymer
US20050058701A1 (en) 2003-01-29 2005-03-17 Yossi Gross Active drug delivery in the gastrointestinal tract
US20050266090A1 (en) 2003-04-29 2005-12-01 Ales Prokop Nanoparticular targeting and therapy
US20050058603A1 (en) 2003-05-02 2005-03-17 Case Western Reserve University Drug delivery system based on polymer nanoshells
KR20030076536A (ko) 2003-09-03 2003-09-26 (주)서봉바이오베스텍 비만억제제로서의 게르마늄 복합광물과 그 용도
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US20060034925A1 (en) 2004-04-02 2006-02-16 Au Jessie L Tumor targeting drug-loaded particles
US20050260276A1 (en) 2004-05-19 2005-11-24 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
US20070036278A1 (en) 2004-06-02 2007-02-15 Audiopoint, Inc. System, method and computer program product for interactive voice notification and product registration
US20060057206A1 (en) 2004-08-19 2006-03-16 Wong Patrick S Controlled release nanoparticle active agent formulation dosage forms and methods
US20060105049A1 (en) 2004-11-12 2006-05-18 Valorisation Recherche Hscm & Universite De Montreal Folic acid-chitosan-DNA nanoparticles
US20060149392A1 (en) 2004-12-07 2006-07-06 Kuo-Huang Hsieh Biomaterials for guided tissue regeneration and drug delivery
US20060193787A1 (en) 2005-01-31 2006-08-31 Si-Shen Feng Nanoparticle-based drug delivery system
US20060188543A1 (en) 2005-01-31 2006-08-24 Si-Shen Feng Nanoparticle coating for drug delivery
WO2007038596A2 (fr) 2005-09-28 2007-04-05 Wyeth Additifs nutritionnels a base de phytosterol

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1980
BISGAIER ET AL., J. LIPID RES., vol. 39, 1998, pages 17 - 30
CARR ET AL., J. NUTR., vol. 126, 1996, pages 1463 - 1469
PELUSO M.R., SCHNEEMAN B.O.: "A food-grade silicon dioxide is hypocholesterolemic in the diet of cholesterol-fed rats", JOURNAL OF NUTRITION, vol. 124, no. 6, 1994, pages 853 - 860
WANG ET AL., ANNU. REV. PHYSIOL., vol. 69, 2007, pages 221 - 48

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3391754A1 (fr) * 2017-04-21 2018-10-24 Tolsa, S.A. Additif alimentaire pour animaux, procédé de préparation et utilisation en tant qu'agent prophylactique contre l'acidose du rumen

Also Published As

Publication number Publication date
US20080292720A1 (en) 2008-11-27
EP2167069A2 (fr) 2010-03-31
ATE530178T1 (de) 2011-11-15
PL2167069T3 (pl) 2012-04-30
EP2167069B1 (fr) 2011-10-26
US8821937B2 (en) 2014-09-02
EP2431043A1 (fr) 2012-03-21
WO2008147807A3 (fr) 2009-03-19
DK2167069T3 (da) 2011-11-21
US8481084B2 (en) 2013-07-09
ES2372652T3 (es) 2012-01-25
US20090186091A1 (en) 2009-07-23
CA2688111A1 (fr) 2008-12-04

Similar Documents

Publication Publication Date Title
US8481084B2 (en) Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
US20200390703A1 (en) Porous silica material for use as a pharmaceutical or dietary active ingredient
US20100119602A1 (en) Phosphate binder with reduced pill burden
US9610255B2 (en) Lycopene and resveratrol dietary supplement
WO2014028587A1 (fr) Compositions comprenant des conjugués chitosane-médicament et procédés permettant de produire et d'utiliser celles-ci
CA2504916A1 (fr) Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
US20070281025A1 (en) Cholesterol-Interacting Layered Phyllosilicates and Methods of Reducing Hypercholesteremia in a Mammal
AU2009219204B2 (en) Methods of treating cardiovascular disorders associated with atherosclerosis
US20120058157A1 (en) Methods of Treating Cardiovascular Disorders Associated with Atherosclerosis
EP1140115A2 (fr) Complexes phospholipidiques de proanthocyanidine a2 comme agents anti-atherosclereux
Gershkovich et al. Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured aluminosilicate compounds
WO2006105643A1 (fr) Compositions pharmaceutiques stabilisees comprenant un inhibiteur de la hmg-coa reductase
CN115068425A (zh) 制备去氧肾上腺素树脂酸盐颗粒的方法与去氧肾上腺素树脂酸盐颗粒及其在药剂中的用途
AU2005205164B2 (en) Novel compositions comprising higher primary alcohols and nicotinic acid and process of preparation thereof
Wu et al. Curcumin nanoparticles and the therapeutic potential of curcumin for musculoskeletal disorders.
US20230405068A1 (en) Radiation-induced fibrosis treatment
WO2016168343A1 (fr) Sels de thiocyanate en tant qu'anti-inflammatoire
TW202015671A (zh) 用於抑制乙醯膽鹼酯酶之萃取物及組合物
AU2015200651A1 (en) Theobromine in combination with an expectorant or a mucolytic for use in therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08780675

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2688111

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008780675

Country of ref document: EP